USRE42575E1 - Engineering of strong, pliable tissues - Google Patents
Engineering of strong, pliable tissues Download PDFInfo
- Publication number
- USRE42575E1 USRE42575E1 US11/529,691 US52969106A USRE42575E US RE42575 E1 USRE42575 E1 US RE42575E1 US 52969106 A US52969106 A US 52969106A US RE42575 E USRE42575 E US RE42575E
- Authority
- US
- United States
- Prior art keywords
- matrix
- cells
- cell
- construct
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000011159 matrix material Substances 0.000 claims abstract description 94
- 238000000034 method Methods 0.000 claims abstract description 40
- 238000002513 implantation Methods 0.000 claims abstract description 24
- 210000003709 heart valve Anatomy 0.000 claims abstract description 22
- 210000004204 blood vessel Anatomy 0.000 claims abstract description 18
- 210000004027 cell Anatomy 0.000 claims description 87
- 210000001519 tissue Anatomy 0.000 claims description 46
- 229920000642 polymer Polymers 0.000 claims description 34
- 229920000954 Polyglycolide Polymers 0.000 claims description 32
- 241001465754 Metazoa Species 0.000 claims description 19
- 210000002889 endothelial cell Anatomy 0.000 claims description 17
- -1 poly(lactide) Polymers 0.000 claims description 16
- 229920002988 biodegradable polymer Polymers 0.000 claims description 12
- 239000004621 biodegradable polymer Substances 0.000 claims description 12
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 11
- 239000003102 growth factor Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 230000000975 bioactive effect Effects 0.000 claims description 7
- 210000000651 myofibroblast Anatomy 0.000 claims description 7
- 229940065514 poly(lactide) Drugs 0.000 claims description 7
- 210000002744 extracellular matrix Anatomy 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 5
- 210000003205 muscle Anatomy 0.000 claims description 5
- 238000010899 nucleation Methods 0.000 claims description 5
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 5
- 239000011148 porous material Substances 0.000 claims description 5
- 210000004509 vascular smooth muscle cell Anatomy 0.000 claims description 5
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 4
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- 210000000107 myocyte Anatomy 0.000 claims description 4
- 229940053128 nerve growth factor Drugs 0.000 claims description 4
- 210000002363 skeletal muscle cell Anatomy 0.000 claims description 4
- 229920001963 Synthetic biodegradable polymer Polymers 0.000 claims description 3
- 230000003328 fibroblastic effect Effects 0.000 claims description 3
- 210000004738 parenchymal cell Anatomy 0.000 claims description 3
- 229920001308 poly(aminoacid) Polymers 0.000 claims description 3
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 claims description 2
- 102400001368 Epidermal growth factor Human genes 0.000 claims description 2
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 2
- 102400000321 Glucagon Human genes 0.000 claims description 2
- 108060003199 Glucagon Proteins 0.000 claims description 2
- 102100031000 Hepatoma-derived growth factor Human genes 0.000 claims description 2
- 101001083798 Homo sapiens Hepatoma-derived growth factor Proteins 0.000 claims description 2
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- 229920002732 Polyanhydride Polymers 0.000 claims description 2
- 229920001710 Polyorthoester Polymers 0.000 claims description 2
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 claims description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims description 2
- 210000003989 endothelium vascular Anatomy 0.000 claims description 2
- 229940116977 epidermal growth factor Drugs 0.000 claims description 2
- 229940011871 estrogen Drugs 0.000 claims description 2
- 239000000262 estrogen Substances 0.000 claims description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 2
- 229960004666 glucagon Drugs 0.000 claims description 2
- 210000002216 heart Anatomy 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 230000000921 morphogenic effect Effects 0.000 claims description 2
- 229920001610 polycaprolactone Polymers 0.000 claims description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 2
- 210000001608 connective tissue cell Anatomy 0.000 claims 1
- 210000003556 vascular endothelial cell Anatomy 0.000 claims 1
- 239000007943 implant Substances 0.000 abstract description 14
- 210000000988 bone and bone Anatomy 0.000 description 25
- 210000000845 cartilage Anatomy 0.000 description 22
- 208000006735 Periostitis Diseases 0.000 description 16
- 210000003460 periosteum Anatomy 0.000 description 16
- 239000000463 material Substances 0.000 description 15
- 230000007547 defect Effects 0.000 description 14
- 230000002792 vascular Effects 0.000 description 14
- 210000002950 fibroblast Anatomy 0.000 description 11
- 238000001574 biopsy Methods 0.000 description 8
- 210000001612 chondrocyte Anatomy 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 239000002131 composite material Substances 0.000 description 7
- 239000004633 polyglycolic acid Substances 0.000 description 7
- 238000009792 diffusion process Methods 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 230000011164 ossification Effects 0.000 description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 230000008520 organization Effects 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 208000018578 heart valve disease Diseases 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 210000002464 muscle smooth vascular Anatomy 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 210000004872 soft tissue Anatomy 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 108010054218 Factor VIII Proteins 0.000 description 2
- 102000001690 Factor VIII Human genes 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 210000002805 bone matrix Anatomy 0.000 description 2
- 230000022159 cartilage development Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 229960000301 factor viii Drugs 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 229960004275 glycolic acid Drugs 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229960000448 lactic acid Drugs 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000001964 muscle biopsy Methods 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 230000000399 orthopedic effect Effects 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- OORRCVPWRPVJEK-UHFFFAOYSA-N 2-oxidanylethanoic acid Chemical compound OCC(O)=O.OCC(O)=O OORRCVPWRPVJEK-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 231100000039 Ames test Toxicity 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000012984 antibiotic solution Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000009246 art therapy Methods 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229920013641 bioerodible polymer Polymers 0.000 description 1
- 210000003364 bony callus Anatomy 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000027879 direct ossification Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000001497 fibrovascular Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000001665 muscle stem cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001432 poly(L-lactide) Polymers 0.000 description 1
- 229920002006 poly(N-vinylimidazole) polymer Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920005594 polymer fiber Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 229920002620 polyvinyl fluoride Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3886—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells comprising two or more cell types
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3633—Extracellular matrix [ECM]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
- A61L27/3645—Connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3843—Connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/507—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials for artificial blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
- A61F2/2415—Manufacturing methods
Definitions
- This invention is generally in the field of reconstruction and augmentation of flexible, strong connective tissue such as arteries and heart valves.
- Tissue engineering is a multidisciplinary science that utilizes basic principles from the life sciences and engineering sciences to create cellular constructs for transplantation.
- the first attempts to culture cells on a matrix for use as artificial skin, which requires formation of a thin three dimensional structure, were described by Yannas and Bell (See, for example, U.S. Pat. Nos. 4,060,081, 4,485,097 and 4,458,678). They used collagen type structures which were seeded with cells, then placed over the denuded area.
- a problem with the use of the collagen matrices was that the rate of degradation is not well controlled.
- Another problem was that cells implanted into the interior of thick pieces of the collagen matrix failed to survive.
- U.S. Pat. No. 4,520,821 to Schmidt describes the use of synthetic polymeric meshes to form linings to repair defects in the urinary tract.
- Epithelial cells were implanted onto the synthetic matrices, which formed a new tubular lining as the matrix degraded.
- the matrix served a two fold purpose—to retain liquid while the cells replicated, and to hold and guide the cells as they replicated.
- Vacanti and Langer recognized that there was a need to have two elements in any matrix used to form organs: adequate structure and surface area to implant a large volume of cells into the body to replace lost function and a matrix formed in a way that allowed adequate diffusion of gases and nutrients throughout the matrix as the cells attached and grew to maintain viability in the absence of vascularization. Once implanted and vascularized, the porosity required for diffusion of the nutrients and gases was no longer critical.
- WO 93/08850 Prevascularized Polymeric Implants for Organ Transplantation
- Massachusetts Institute of Technology and Children's Medical Center Corporation disclosed implantation of relatively rigid, non-compressible porous matrices which are allowed to become vascularized, then seeded with cells. It was difficult to control the extent of ingrowth of fibrous tissue, however, and to obtain uniform distribution of cells throughout the matrix when they were subsequently injected into the matrix.
- connective tissue such as bone and cartilage
- soft tissue such as hepatocytes, intestine, endothelium
- specific structures such as ureters.
- Valve replacement is the state-of-the art therapy for end-stage valve disease.
- Heart valve replacement with either nonliving xenografts or mechanical protheses is an effective therapy for valvular heart disease.
- both types of heart valve replacements have limitations, including finite durability, foreign body reaction or rejection and the inability of the non-living structures to grow, repair and remodel, as well as the necessity of life-long anticoagulation for the mechanical prothesis.
- the construction of a tissue engineered living heart valve could eliminate these problems.
- Atherosclerosis and cardiovascular disease are also major causes of morbidity and mortality. More than 925,000 Americans died from heart and blood vessels disease in 1992, and an estimated 468,000 coronary artery bypass surgeries were performed on 393,000 patients. This does not include bypass procedures, for peripheral vascular disease.
- internal mammary and saphenous vein grafts are the most frequently used native grafts for coronary bypass surgery. However, with triple and quadruple bypasses and often the need for repeat bypass procedures, sufficient native vein grafts can be a problem. Surgeons must frequently look for vessels other than the internal mammary and saphenous vessels.
- Tissue engineered blood vessels may offer a substitute for small caliber vessels for bypass surgery and replacement of diseased vessels.
- structures are created by seeding of fibrous or porous polymeric matrices with dissociated cells which are useful for a variety of applications, ranging from soft tissues formed of parenchymal cells such as hepatocytes, to tissues having structural elements such as heart valves and blood vessels, to cartilage and bone.
- the polymeric matrices are implanted into a human or animal to allow ingrowth of fibroblastic tissue, then implanted at the site where the structure is needed, either alone or seeded with defmed defined cell populations.
- the synthetic matrix serves several purposes. It functions as a cell delivery system that enables the organized transplantation of large numbers of cells into the body.
- the matrix acts as a scaffold providing three-dimensional space for cell growth.
- the matrix functions as a template providing structural cues for tissue development. In the case of tissues have specific requirements for structure and mechanical strength, the polymer temporarily provides the biomechanical properties of the final construct, giving the cells time to lay down their own extracellular matrix which ultimately is responsible for the biomechanical profile of the construct.
- the scaffold also determines the limits of tissue growth and thereby determines the ultimate shape of tissue engineered construct. Cells implanted on a matrix proliferate only to the edges of the matrix; not beyond.
- the matrices must have sufficient surface area and exposure to nutrients such that cellular growth and differentiation can occur prior to the ingrowth of blood vessels following implantation. This is not a limiting feature where the matrix is implanted and ingrowth of tissue from the body occurs, prior to seeding of the matrix with dissociated cells.
- the organization of the tissue may be regulated by the microstructure of the matrix. Specific pore sizes and structures may be utilized to control the pattern and extent of fibrovascular tissue ingrowth from the host, as well as the organization of the implanted cells.
- the surface geometry and chemistry of the matrix may be regulated to control the adhesion, organization, and function of implanted cells or host cells.
- the matrix is formed of polymers having a fibrous structure which has sufficient interstitial spacing to allow for free diffusion of nutrients and gases to cells attached to the matrix surface. This spacing is typically in the range of 100 to 300 microns, although closer spacings can be used if the matrix is implanted, blood vessels allowed to infiltrate the matrix, then the cells are seeded into the matrix.
- fibrous includes one or more fibers that is entwined with itself, multiple fibers in a woven or non-woven mesh, and sponge like devices.
- the matrix should be a pliable, non-toxic, injectable porous template for vascular ingrowth.
- the pores should allow vascular ingrowth and the injection of cells in a desired density and region(s) of the matrix without damage to the cells. These are generally interconnected pores in the range of between approximately 100 and 300 microns.
- the matrix should be shaped to maximize surface area, to allow adequate diffusion of nutrients and growth factors to the cells and to allow the ingrowth of new blood vessels and connective tissue.
- the overall, or external, matrix configuration is dependent on the tissue which is to reconstructed or augmented.
- the shape can also be obtained using struts, as described below, to impart resistance to mechanical forces and thereby yield the desired shape. Examples include heart valve “leaflets” and tubes.
- bioerodible or “biodegradable”, as used herein refers to materials which are enzymatically or chemically degraded in vivo into simpler chemical species. Either natural or synthetic polymers can be used to form the matrix, although synthetic biodegradable polymers are preferred for reproducibility and controlled release kinetics.
- Synthetic polymers that can be used include bioerodible polymers such as poly(lactide) (PLA), poly(glycolic acid) (PGA), poly(lactide-co-glycolide) (PLGA), poly(caprolactone), polycarbonates, polyamides, polyanhydrides, polyamino acids, polyortho esters, polyacetals, polycyanoacrylates and degradable polyurethanes, and non-erodible polymers such as polyacrylates, ethylene-vinyl acetate polymers and other acyl substituted cellulose acetates and derivatives thereof, non-erodible polyurethanes, polystyrenes, polyvinyl chloride, polyvinyl fluoride, poly(vinyl imidazole), chlorosulphonated polyolifins, polyethylene oxide, polyvinyl alcohol, teflon®, and nylon.
- bioerodible polymers such as poly(lactide) (PLA), poly(glycolic acid
- non-degradable materials can be used to form the matrix or a portion of the matrix, they are not preferred.
- the preferred non-degradable material for implantation of a matrix which is prevascularized prior to implantation of dissociated cells is a polyvinyl alcohol sponge, or alkylation, and acylation derivatives thereof, including esters.
- a non-absorbable polyvinyl alcohol sponge is available commercially as IvalonTM, from Unipoint Industries. Methods for making this material are described in U.S. Pat. Nos.
- natural polymers include proteins such as albumin, collagen, synthetic polyamino acids, and prolamines, and polysaccharides such as alginate, heparin, and other naturally occurring biodegradable polymers of sugar units. These are not preferred because of difficulty with quality control and lack of reproducible, defined degradation characteristics.
- PLA, PGA and PLA/PGA copolymers are particularly useful for forming the biodegradable matrices. These are synthetic, biodegradable ⁇ -hydroxy acids with a long history of medical use.
- PLA polymers are usually prepared from the cyclic esters of lactic acids. Both L(+) and D( ⁇ ) forms of lactic acid can be used to prepare the PLA polymers, as well as the optically inactive DL-lactic acid mixture of D( ⁇ ) and L(+) lactic acids. Methods of preparing polylactides are well documented in the patent literature. The following U.S.
- Patents the teachings of which are hereby incorporated by reference, describe in detail suitable polylactides, their properties and their preparation: 1,995,970 to Dorough; 2,703,316 to Schneider, 2,758,987 to Salzberg; 2,951,828 to Zeile; 2,676,945 to Higgins; and 2,683,136; 3,531,561 to Trehu.
- PGA is the homopolymer of glycolic acid (hydroxyacetic acid).
- glycolic acid hydroxyacetic acid
- glycolic acid is initially reacted with itself to form the cyclic ester glycolide, which in the presence of heat and a catalyst is convened to a high molecular weight linear-chain polymer.
- PGA polymers and their properties are described in more detail in Cyanamid Research Develops World's First Synthetic Absorbable Suture”, Chemistry and Industry, 905 (1970).
- the erosion of the matrix is related to the molecular weights of the polymer, for example, PLA, PGA or PLA/PGA.
- a preferred material is poly(lactide-co-glycolide) (50:50), which degrades in about six weeks following implantation (between one and two months) and poly(glycolic acid).
- All polymers for use in the matrix must meet the mechanical and biochemical parameters necessary to provide adequate support for the cells with subsequent growth and proliferation.
- the polymers can be characterized with respect to mechanical properties such as tensile strength using an Instron tester, for polymer molecular weight by gel permeation chromatography (GPC), glass transition temperature by differential scanning calorimetry (DSC) and bond structure by infrared (IR) spectroscopy, with respect to toxicology by initial screening tests involving Ames assays and in vitro teratogenicity assays, and implantation studies in animals for immunogenicity, inflammation, release and degradation studies.
- GPC gel permeation chromatography
- DSC differential scanning calorimetry
- IR infrared
- attachment of the cells to the polymer is enhanced by coating the polymers with compounds such as basement membrane components, agar, agarose, gelatin, gum arabic, collagens types I, II, III, IV, and V, fibronectin, laminin, glycosaminoglycans, polyvinyl alcohol, mixtures thereof, and other hydrophilic and peptide attachment materials known to those skilled in the art of cell culture.
- a preferred material for coating the polymeric matrix is polyvinyl alcohol or collagen.
- struts can be biodegradable or non-degradable polymers which are inserted to form a more defined shape than is obtained using the cell-matrices.
- An analogy can be made to a corset, with the struts acting as “stays” to push the surrounding tissue and skin up and away from the implanted cells.
- the struts are implanted prior to or at the time of implantation of the cell-matrix structure.
- the struts are formed of a polymeric material of the same type as can be used to form the matrix, as listed above, having sufficient strength to resist the necessary mechanical forces.
- bioactive molecules it may be desirable to add bioactive molecules to the cells.
- bioactive molecules can be delivered using the matrices described herein. These are referred to generically herein as “factors” or “bioactive factors”.
- the bioactive factors are growth factors, angiogenic factors, compounds selectively inhibiting ingrowth of fibroblast tissue such as antiinflammatories, and compounds selectively inhibiting growth and proliferation of transformed (cancerous) cells. These factors may be utilized to control the growth and function of implanted cells, the ingrowth of blood vessels into the forming tissue, and/or the deposition and organization of fibrous tissue around the implant.
- growth factors examples include heparin binding growth factor (hbgf), transforming growth factor alpha or beta (TGF ⁇ ), alpha fibroblastic growth factor (FGF), epidermal growth factor (TGF), vascular endothelium growth factor (VEGF), some of which are also angiogenic factors.
- Other factors include hormones such as insulin, glucagon, and estrogen.
- NGF nerve growth factor
- MMP muscle morphogenic factor
- Steroidal antiinflammatories can be used to decrease inflammation to the implanted matrix, thereby decreasing the amount of fibroblast tissue growing into the matrix.
- the bioactive factors are incorporated to between one and 30% by weight, although the factors can be incorporated to a weight percentage between 0.01 and 95 weight percentage.
- Bioactive molecules can be incorporated into the matrix and released over time by diffusion and/or degradation of the matrix, they can be suspended with the cell suspension, they can be incorporated into microspheres which are suspended with the cells or attached to or incorporated within the matrix, or some combination thereof.
- Microspheres would typically be formed of materials similar to those forming the matrix, selected for their release properties rather than structural properties. Release properties can also be determined by the size and physical characteristics of the microspheres.
- Cells to be implanted are dissociated using standard techniques such as digestion with a collagenase, trypsin or other protease solution.
- Preferred cell types are mesenchymal cells, especially smooth or skeletal muscle cells, myocytes (muscle stem cells), fibroblasts, chondrocytes, adipocytes, fibromyoblasts, and ectodermal cells, including ductile and skin cells, hepatocytes, Islet cells, cells present in the intestine, and other parenchymal cells, osteoblasts and other cells forming bone or cartilage. In some cases it may also be desirable to include nerve cells.
- Cells can be normal or genetically engineered to provide additional or normal function. Methods for genetically engineering cells with retroviral vectors, polyethylene glycol, or other methods known to those skilled in the art can be used.
- Cells are preferably autologous cells, obtained by biopsy and expanded in culture, although cells from close relatives or other donors of the same species may be used with appropriate immunosuppression.
- Immunologically inert cells such as embryonic or fetal cells, stem cells, and cells genetically engineered to avoid the need for immunosuppression can also be used. Methods and drugs for immunosuppression are known to those skilled in the art of transplantation.
- a preferred compound is cyclosporin using the recommended dosages.
- cells are obtained by biopsy and expanded in culture for subsequent implantation.
- Cells can be easily obtained through a biopsy anywhere in the body, for example, skeletal muscle biopsies can be obtained easily from the arm, forearm, or lower extremities, and smooth muscle can be obtained from the area adjacent to the subcutaneous tissue throughout the body.
- the area to be biopsied can be locally anesthetized with a small amount of lidocaine injected subcutaneously.
- a small patch of lidocaine jelly can be applied over the area to be biopsied and left in place for a period of 5 to 20 minutes, prior to obtaining biopsy specimen.
- the biopsy can be effortlessly obtained with the use of a biopsy needle, a rapid action needle which makes the procedure extremely simple and almost painless. With the addition of the anesthetic agent, the procedure would be entirely painless.
- This small biopsy core of either skeletal or smooth muscle can then be transferred to media consisting of phosphate buffered saline.
- the biopsy specimen is then transferred to the lab where the muscle can be grown utilizing the explant technique, wherein the muscle is divided into very pieces which are adhered to culture plate, and serum containing media is added.
- the muscle biopsy can be enzymatically digested with agents such as trypsin and the cells dispersed in a culture plate with any of the routinely used medias. After cell expansion within the culture plate, the cells can be easily passaged utilizing the usual technique until an adequate number of cells is achieved.
- the present method uses the recipient or an animal as the initial bioreactor to form a fibrous tissue-polymeric construct which optionally can be seeded with other cells and implanted.
- the matrix becomes infiltrated with fibrous tissue and/or blood vessels over a period ranging from between one day and a few weeks, most preferably one and two weeks.
- the matrix is then removed and implanted at the site where it is needed.
- the matrix is formed of polymer fibers having a particular desired shape, that is implanted subcutaneously.
- the implant is retrieved surgically, then one or more defined cell types distributed onto and into the fibers.
- the matrix is seeded with cells of a defined type, implanted until fibrous tissue has grown into the matrix, then the matrix removed, optionally cultured further in vitro, then reimplanted at a desired site.
- the resulting structures are dictated by the matrix construction, including architecture, porosity (% void volume and pore diameter), polymer nature including composition, crystallinity, molecular weight, and degradability, hydrophobicity, and the inclusion of other biologically active molecules.
- valves are heart valves and valves of the type used for ventricular shunts for treatment of hydrocephaly.
- a similar structure could be used for an ascites shunt in the abdomen where needed due to liver disease or in the case of a lymphatic obstructive disease.
- tubular structures include blood vessels, intestine, ureters, and fallopian tubes.
- the structures are formed at a site other than where they are ultimately required. This is particularly important in the case of tubular structures and valves, where integrity to fluid is essential, and where the structure is subjected to repeated stress and strain.
- Valvular heart disease is a significant cause of morbidity and mortality. Construction of a tissue engineered valve using living autologous cells offers advantages over currently used mechanical or glutaraldehyde fixed xenograft valves.
- a tissue engineered valve was constructed by seeding a synthetic polyglycolic acid (PGA) fiber based matrix with dissociated fibroblasts and endothelial cells harvested from a donor sheep heart valve. The cells were grown to confluence and split several times to increase the cell number. A mixed cell population including myofibroblasts and endothelial cells was obtained. The endothelial cells were labeled with an Ac-Dil-LDL fluorescent antibody obtained from a commercial source and sorted in a cell-sorting machine to yield a nearly pure endothelial cell population (LDL+) and a mixed cell population containing myofibroblasts and endothelial cells (LDL ⁇ ).
- PGA polyglycolic acid
- a PGA mesh (density 76.9 mg/ml and thickness 0.68 mm) was seeded with the mixed cell population and grown in culture. When the myofibroblasts reached confluence, endothelial cells were seeded onto the surface of the fibroblast/mesh constructs and grown into a single monolayer.
- vascular smooth muscle tubular structures using a biodegradable polyglycolic acid polymer scaffold have been developed.
- the technique involves the isolation and culture of vascular smooth muscle cells, the reconstruction of a vascular wall using biodegradable polymer, and formation of the neo-tissue tubes in vitro.
- the feasibility of engineering vascular structures by coculturing endothelial cells with fibroblasts and smooth muscle cells on a synthetic biodegradable matrix in order to create tubular constructs which histologically resemble native vascular structures was also demonstrated.
- PGA centimeter polyglycolic acid
- smooth muscle cells were obtained by harvesting the media from the artery of a lamb using standard explant techniques. Cells were expanded in culture through repeated passages and then seeded on the biodegradable polymer scaffold at a density of 1 ⁇ 10 6 cells per cm 2 of polymer. The cell-polymer constructs were formed into tubes with internal diameters ranging from 2 mm to 5 mm and maintained in vitro for 6 to 8 weeks.
- PGA Polyglycolic acid
- Bovine periosteum harvested from fresh calf limbs, was placed either directly onto PGA polymer (1 ⁇ 1 cm) or onto tissue culture dishes for periosteal cell isolation.
- the periosteum/PGA construct was cultured for one week in MEM 199 culture media with antibiotics and ascorbic acid, then implanted into the dorsal subcutaneous space of nude mice.
- Periosteal cell cultured from pieces of periosteum for two weeks, were isolated into cell suspension and seeded (approximately 1 to 3 ⁇ 10 7 cells) onto PGA polymer (1 ⁇ 1 cm); after one week in culture, the periosteal cell seeded polymer was implanted into the subcutaneous space of nude mice. Specimens, harvested at 4, 8, and 14 week intervals, were evaluated grossly and histologically.
- the periosteum/PGA constructs showed an organized cartilage matrix with early evidence of bone formation at four weeks, a mixture of bone and cartilage at 8 weeks, and a complete bone matrix at 14 weeks. Constructs created from periosteal cells seeded onto polymer showed presence of disorganized cartilage at 4 and 8 weeks, and a mixture of bone and cartilage at 14 weeks. Periosteum placed directly onto polymer will form an organized cartilage and bone matrix earlier than constructs formed from periosteal cell seeded polymer. This data indicates that PGA is an effective scaffold for periosteal cell attachment and migration to produce bone, which may offer new approaches to reconstructive surgery.
- the aim of this study was to determine if new vascularized bone could be engineered by transplantation of osteoblast around existing vascular pedicle using biodegradable polymers as cell delivery devices, to be used to reconstruct weight bearing bony defects.
- Osteoblast and chondryocytes were isolated from calf periosteum and articular cartilage, cultured in vitro for three weeks, then seeded onto a 1 ⁇ 1 cm non-woven polyglycolic acid (PGA) mesh. After maintenance in vitro for one week, cell-polymer constructs were wrapped around saphenous vessels, and implanted into athymic rats for 8 weeks. The implants showed gross and histological evidence of vascularized bone or cartilage. At this time, bilateral 0.8 cm femoral shaft defect were created in the same rat, and fixed in position with a 3 cm craniofacial titanium miniplate. The new engineered bone/cartilage construct was then transferred to the femoral defect on its bilateral vascular pedicle.
- PGA polyglycolic acid
- a total of 30 femoral defects were repaired in three groups of animals (each group composed of five animals with defects).
- Animals in Group 1 received implants composed of vascularized bone constructs, animals in Group 2 with vascular cartilage constructs, and Group 3 animals with blank polymer only.
- Group 1 defect showed evidence of new bone formation around the defect. Neither Group 2 nor Group 3 defect showed any radiographic evidence of healing or bone formation. Grossly, Group 1 animals developed exuberant bony callus formation and healing of the defect. The animals in Group 2 showed filling of the bony defect with cartilaginous tissue, whereas all of the animals in Group 3 either developed a fibrous non-union or simple separation of both bony fragments with soft tissue invasion of the defect. The histological studies showed new bone formation in all Group 1 animals, new cartilage formation in all Group 2 animals, and fibrous tissue invasion in all Group 3 animals.
- the ability to construct a composite structure of bone and cartilage offers a significant modality in reconstructive plastic and orthopedic surgery.
- the following study was conducted to engineer a bone and cartilage composite structure using periosteum, chondrocytes and biodegradable polymer and to direct bone and cartilage formation by selectively placing periosteum and chondrocytes onto the polymer scaffold.
- Bovine periosteum and cartilage were harvested from newborn calf limbs. Periosteum (1.5 ⁇ 2.0 cm) was wrapped around a polyglycolic acid/poly L-lactic acid co-polymer tube (3 cm in length, 3 mm in diameter), leaving the ends exposed. The cartilage pieces were enzymatically digested with collagenase, and chondrocytes (2 ⁇ 10 7 cells) were seeded onto each end of the exposed polymer. The composite construct was cultured for seven days in Medium 199 with antibiotics, fetal bovine serum, and ascorbic acid at 37° C. with 5% CO 2 . Eight constructs were then implanted into the dorsal subcutaneous space of eight nude mice. After 8 to 14 weeks in vivo, the implants were harvested and evaluated grossly and histologically.
- All implants formed into cylindrical shapes, flattened at the ends.
- the central portion of the implant formed into a bony matrix and the ends of the specimens formed into cartilage, approximately where the periosteum and chondrocytes were placed. Histological sections showed an organized matrix of bone and cartilage with a distinct transition between bone and cartilage.
- periosteum and chondrocytes placed onto a biodegradable polymer will form into a composite tissue of bone and cartilage. Moreoever, bone and cartilage composite formation with selective placement of periosteum and chondrocytes on a biodegradable polymer scaffold was shown.
- a PGA mesh as described in Example 1 or 2 was implanted subcutaneously in an animal, then removed after a period of one to two weeks. Fibroblasts migrated into the polymeric mesh while it was implanted. The implant was then seeded with other cells such as chondrocytes or endothelial cells and cultured in vitro for an additional period of time.
- the resulting implant was shown to have greater mechanical strength and pliability than implants formed solely by seeding of dissociated cells.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Materials For Medical Uses (AREA)
Abstract
It has been discovered that improved yields of engineered tissue following implantation, and engineered tissue having enhanced mechanical strength and flexibility or pliability, can be obtained by implantation, preferably subcutaneously, of a fibrous polymeric matrix for a period of time sufficient to obtain ingrowth of fibrous tissue and/or blood vessels, which is the removed for subsequent implantation at the site where the implant is desired. The matrix is optionally seeded prior to the first implantation, after ingrowth of the fibrous tissue, or at the time of reimplantation. The time required for fibrous ingrowth typically ranges from days to weeks. The method is particularly useful in making valves and tubular structures, especially heart valves and blood vessels.
Description
ThisMore than one reissue application has been filed for the reissue of U.S. Pat. No. 6,348,069. This application is a divisional of U.S. Reissue application Ser. No. 10/782,750 filed Feb. 19, 2004, which is a reissue of U.S. Pat. No. 6,348,069, which issued Feb. 19, 2002, from U.S. Ser. No. 09/185,360 filed Nov. 3, 1998, which is a divisional of U.S. Ser. No. 08/445,280 filed May 19, 1995 now U.S. Pat. No. 5,855,610.
This invention is generally in the field of reconstruction and augmentation of flexible, strong connective tissue such as arteries and heart valves.
Tissue engineering is a multidisciplinary science that utilizes basic principles from the life sciences and engineering sciences to create cellular constructs for transplantation. The first attempts to culture cells on a matrix for use as artificial skin, which requires formation of a thin three dimensional structure, were described by Yannas and Bell (See, for example, U.S. Pat. Nos. 4,060,081, 4,485,097 and 4,458,678). They used collagen type structures which were seeded with cells, then placed over the denuded area. A problem with the use of the collagen matrices was that the rate of degradation is not well controlled. Another problem was that cells implanted into the interior of thick pieces of the collagen matrix failed to survive.
U.S. Pat. No. 4,520,821 to Schmidt describes the use of synthetic polymeric meshes to form linings to repair defects in the urinary tract. Epithelial cells were implanted onto the synthetic matrices, which formed a new tubular lining as the matrix degraded. The matrix served a two fold purpose—to retain liquid while the cells replicated, and to hold and guide the cells as they replicated.
In European Patent Application No. 88900726.6 “Chimeric Neomorphogenesis of Organs by Controlled Cellular Implantation Using Artificial Matrices” by Children's Hospital Center Corporation and Massachusetts Institute of Technology, a method of culturing dissociated cells on biocompatible, biodegradable matrices for subsequent implantation into the body was described. This method was designed to overcome a major problem with previous attempts to culture cells to form three dimensional structures having a diameter of greater than that of skin. Vacanti and Langer recognized that there was a need to have two elements in any matrix used to form organs: adequate structure and surface area to implant a large volume of cells into the body to replace lost function and a matrix formed in a way that allowed adequate diffusion of gases and nutrients throughout the matrix as the cells attached and grew to maintain viability in the absence of vascularization. Once implanted and vascularized, the porosity required for diffusion of the nutrients and gases was no longer critical.
To overcome some of the limitations inherent in the design of the porous structures which support cell growth throughout the matrix solely by diffusion, WO 93/08850 “Prevascularized Polymeric Implants for Organ Transplantation” by Massachusetts Institute of Technology and Children's Medical Center Corporation disclosed implantation of relatively rigid, non-compressible porous matrices which are allowed to become vascularized, then seeded with cells. It was difficult to control the extent of ingrowth of fibrous tissue, however, and to obtain uniform distribution of cells throughout the matrix when they were subsequently injected into the matrix.
Many tissues have now been engineered using these methods, including connective tissue such as bone and cartilage, as well as soft tissue such as hepatocytes, intestine, endothelium, and specific structures, such as ureters. There remains a need to improve the characteristic mechanical and physical properties of the resulting tissues, which in some cases does not possess the requisite strength and pliability to perform its necessary function in vivo. Examples of particular structures include heart valves and blood vessels.
Despite major advances in its treatment over the past thirty-five years, valvular heart disease is still a major cause of morbidity and mortality in the United States. Each year 10,000 Americans die as a direct result of this problem. Valve replacement is the state-of-the art therapy for end-stage valve disease. Heart valve replacement with either nonliving xenografts or mechanical protheses is an effective therapy for valvular heart disease. However, both types of heart valve replacements have limitations, including finite durability, foreign body reaction or rejection and the inability of the non-living structures to grow, repair and remodel, as well as the necessity of life-long anticoagulation for the mechanical prothesis. The construction of a tissue engineered living heart valve could eliminate these problems.
Atherosclerosis and cardiovascular disease are also major causes of morbidity and mortality. More than 925,000 Americans died from heart and blood vessels disease in 1992, and an estimated 468,000 coronary artery bypass surgeries were performed on 393,000 patients. This does not include bypass procedures, for peripheral vascular disease. Currently, internal mammary and saphenous vein grafts are the most frequently used native grafts for coronary bypass surgery. However, with triple and quadruple bypasses and often the need for repeat bypass procedures, sufficient native vein grafts can be a problem. Surgeons must frequently look for vessels other than the internal mammary and saphenous vessels. While large diameter (0.5 mm internal diameter) vascular grafts of dacron or polytetraflorethylene (PTFE) have been successful, small caliber synthetic vascular grafts frequently do not remain patent over time. Tissue engineered blood vessels may offer a substitute for small caliber vessels for bypass surgery and replacement of diseased vessels.
It is therefore an object of the present invention to provide a method for making tissue engineered constructs which have improved mechanical strength and flexibility.
It is a further object of the present invention to provide a method and materials for making valves and vessels which can withstand repeated stress and strain.
It is another object of the present invention to provide a method improving yields of engineered tissues following implantation.
It has been discovered that improved yields of engineered tissue following implantation, and engineered tissue having enhanced mechanical strength and flexibility or pliability, can be obtained by implantation, preferably subcutaneously, of a fibrous polymeric matrix for a period of time sufficient to obtain ingrowth of fibrous tissue and/or blood vessels, which is then removed for subsequent implantation at the site where the implant is desired. The matrix is optionally seeded prior to the first implantation, after ingrowth of the fibrous tissue, or at the time of reimplantation. The time required for fibrous ingrowth typically ranges from days to weeks. The method is particularly useful in making valves and tubular structures, especially heart valves and blood vessels.
Examples demonstrate construction of blood vessels, heart valves and bone and cartilage composite structures.
As described herein, structures are created by seeding of fibrous or porous polymeric matrices with dissociated cells which are useful for a variety of applications, ranging from soft tissues formed of parenchymal cells such as hepatocytes, to tissues having structural elements such as heart valves and blood vessels, to cartilage and bone. In a particular improvement over the prior art methods, the polymeric matrices are implanted into a human or animal to allow ingrowth of fibroblastic tissue, then implanted at the site where the structure is needed, either alone or seeded with defmed defined cell populations.
I. Matrix Fabrication
The synthetic matrix serves several purposes. It functions as a cell delivery system that enables the organized transplantation of large numbers of cells into the body. The matrix acts as a scaffold providing three-dimensional space for cell growth. The matrix functions as a template providing structural cues for tissue development. In the case of tissues have specific requirements for structure and mechanical strength, the polymer temporarily provides the biomechanical properties of the final construct, giving the cells time to lay down their own extracellular matrix which ultimately is responsible for the biomechanical profile of the construct. The scaffold also determines the limits of tissue growth and thereby determines the ultimate shape of tissue engineered construct. Cells implanted on a matrix proliferate only to the edges of the matrix; not beyond.
Matrix Architecture
As previously described, for a tissue to be constructed, successfully implanted, and function, the matrices must have sufficient surface area and exposure to nutrients such that cellular growth and differentiation can occur prior to the ingrowth of blood vessels following implantation. This is not a limiting feature where the matrix is implanted and ingrowth of tissue from the body occurs, prior to seeding of the matrix with dissociated cells.
The organization of the tissue may be regulated by the microstructure of the matrix. Specific pore sizes and structures may be utilized to control the pattern and extent of fibrovascular tissue ingrowth from the host, as well as the organization of the implanted cells. The surface geometry and chemistry of the matrix may be regulated to control the adhesion, organization, and function of implanted cells or host cells.
In the preferred embodiment, the matrix is formed of polymers having a fibrous structure which has sufficient interstitial spacing to allow for free diffusion of nutrients and gases to cells attached to the matrix surface. This spacing is typically in the range of 100 to 300 microns, although closer spacings can be used if the matrix is implanted, blood vessels allowed to infiltrate the matrix, then the cells are seeded into the matrix. As used herein, “fibrous” includes one or more fibers that is entwined with itself, multiple fibers in a woven or non-woven mesh, and sponge like devices.
The matrix should be a pliable, non-toxic, injectable porous template for vascular ingrowth. The pores should allow vascular ingrowth and the injection of cells in a desired density and region(s) of the matrix without damage to the cells. These are generally interconnected pores in the range of between approximately 100 and 300 microns. The matrix should be shaped to maximize surface area, to allow adequate diffusion of nutrients and growth factors to the cells and to allow the ingrowth of new blood vessels and connective tissue.
The overall, or external, matrix configuration is dependent on the tissue which is to reconstructed or augmented. The shape can also be obtained using struts, as described below, to impart resistance to mechanical forces and thereby yield the desired shape. Examples include heart valve “leaflets” and tubes.
Polymers
The term “bioerodible”, or “biodegradable”, as used herein refers to materials which are enzymatically or chemically degraded in vivo into simpler chemical species. Either natural or synthetic polymers can be used to form the matrix, although synthetic biodegradable polymers are preferred for reproducibility and controlled release kinetics. Synthetic polymers that can be used include bioerodible polymers such as poly(lactide) (PLA), poly(glycolic acid) (PGA), poly(lactide-co-glycolide) (PLGA), poly(caprolactone), polycarbonates, polyamides, polyanhydrides, polyamino acids, polyortho esters, polyacetals, polycyanoacrylates and degradable polyurethanes, and non-erodible polymers such as polyacrylates, ethylene-vinyl acetate polymers and other acyl substituted cellulose acetates and derivatives thereof, non-erodible polyurethanes, polystyrenes, polyvinyl chloride, polyvinyl fluoride, poly(vinyl imidazole), chlorosulphonated polyolifins, polyethylene oxide, polyvinyl alcohol, teflon®, and nylon. Although non-degradable materials can be used to form the matrix or a portion of the matrix, they are not preferred. The preferred non-degradable material for implantation of a matrix which is prevascularized prior to implantation of dissociated cells is a polyvinyl alcohol sponge, or alkylation, and acylation derivatives thereof, including esters. A non-absorbable polyvinyl alcohol sponge is available commercially as Ivalon™, from Unipoint Industries. Methods for making this material are described in U.S. Pat. Nos. 2,609,347 to Wilson; 2,653,917 to Hammon, 2,659,935 to Hammon, 2,664,366 to Wilson, 2,664,367 to Wilson, and 2,846,407 to Wilson, the teachings of which are incorporated by reference herein. These materials are all commercially available.
Examples of natural polymers include proteins such as albumin, collagen, synthetic polyamino acids, and prolamines, and polysaccharides such as alginate, heparin, and other naturally occurring biodegradable polymers of sugar units. These are not preferred because of difficulty with quality control and lack of reproducible, defined degradation characteristics.
PLA, PGA and PLA/PGA copolymers are particularly useful for forming the biodegradable matrices. These are synthetic, biodegradable α-hydroxy acids with a long history of medical use. PLA polymers are usually prepared from the cyclic esters of lactic acids. Both L(+) and D(−) forms of lactic acid can be used to prepare the PLA polymers, as well as the optically inactive DL-lactic acid mixture of D(−) and L(+) lactic acids. Methods of preparing polylactides are well documented in the patent literature. The following U.S. Patents, the teachings of which are hereby incorporated by reference, describe in detail suitable polylactides, their properties and their preparation: 1,995,970 to Dorough; 2,703,316 to Schneider, 2,758,987 to Salzberg; 2,951,828 to Zeile; 2,676,945 to Higgins; and 2,683,136; 3,531,561 to Trehu.
PGA is the homopolymer of glycolic acid (hydroxyacetic acid). In the conversion of glycolic acid to poly(glycolic acid), glycolic acid is initially reacted with itself to form the cyclic ester glycolide, which in the presence of heat and a catalyst is convened to a high molecular weight linear-chain polymer. PGA polymers and their properties are described in more detail in Cyanamid Research Develops World's First Synthetic Absorbable Suture”, Chemistry and Industry, 905 (1970).
The erosion of the matrix is related to the molecular weights of the polymer, for example, PLA, PGA or PLA/PGA. The higher molecular weights, weight average molecular weights of 90,000 or higher, result in polymer matrices which retain their structural integrity for longer periods of time; while lower molecular weights, weight average molecular weights of 30,000 or less, result in both slower release and shorter matrix lives. A preferred material is poly(lactide-co-glycolide) (50:50), which degrades in about six weeks following implantation (between one and two months) and poly(glycolic acid).
All polymers for use in the matrix must meet the mechanical and biochemical parameters necessary to provide adequate support for the cells with subsequent growth and proliferation. The polymers can be characterized with respect to mechanical properties such as tensile strength using an Instron tester, for polymer molecular weight by gel permeation chromatography (GPC), glass transition temperature by differential scanning calorimetry (DSC) and bond structure by infrared (IR) spectroscopy, with respect to toxicology by initial screening tests involving Ames assays and in vitro teratogenicity assays, and implantation studies in animals for immunogenicity, inflammation, release and degradation studies.
Polymer Coatings
In some embodiments, attachment of the cells to the polymer is enhanced by coating the polymers with compounds such as basement membrane components, agar, agarose, gelatin, gum arabic, collagens types I, II, III, IV, and V, fibronectin, laminin, glycosaminoglycans, polyvinyl alcohol, mixtures thereof, and other hydrophilic and peptide attachment materials known to those skilled in the art of cell culture. A preferred material for coating the polymeric matrix is polyvinyl alcohol or collagen.
Struts
In some embodiments it may be desirable to create additional structure using devices provided for support, referred to herein as “struts”. These can be biodegradable or non-degradable polymers which are inserted to form a more defined shape than is obtained using the cell-matrices. An analogy can be made to a corset, with the struts acting as “stays” to push the surrounding tissue and skin up and away from the implanted cells. In a preferred embodiment, the struts are implanted prior to or at the time of implantation of the cell-matrix structure. The struts are formed of a polymeric material of the same type as can be used to form the matrix, as listed above, having sufficient strength to resist the necessary mechanical forces.
Additives to Polymer Matrices
In some embodiments it may be desirable to add bioactive molecules to the cells. A variety of bioactive molecules can be delivered using the matrices described herein. These are referred to generically herein as “factors” or “bioactive factors”.
In the preferred embodiment, the bioactive factors are growth factors, angiogenic factors, compounds selectively inhibiting ingrowth of fibroblast tissue such as antiinflammatories, and compounds selectively inhibiting growth and proliferation of transformed (cancerous) cells. These factors may be utilized to control the growth and function of implanted cells, the ingrowth of blood vessels into the forming tissue, and/or the deposition and organization of fibrous tissue around the implant.
Examples of growth factors include heparin binding growth factor (hbgf), transforming growth factor alpha or beta (TGFβ), alpha fibroblastic growth factor (FGF), epidermal growth factor (TGF), vascular endothelium growth factor (VEGF), some of which are also angiogenic factors. Other factors include hormones such as insulin, glucagon, and estrogen. In some embodiments it may be desirable to incorporate factors such as nerve growth factor (NGF) or muscle morphogenic factor (MMP).
Steroidal antiinflammatories can be used to decrease inflammation to the implanted matrix, thereby decreasing the amount of fibroblast tissue growing into the matrix.
These factors are known to those skilled in the art and are available commercially or described in the literature. In vivo dosages are calculated based on in vitro release studies in cell culture; an effective dosage is that dosage which increases cell proliferation or survival as compared with controls, as described in more detail in the following examples. Preferably, the bioactive factors are incorporated to between one and 30% by weight, although the factors can be incorporated to a weight percentage between 0.01 and 95 weight percentage.
Bioactive molecules can be incorporated into the matrix and released over time by diffusion and/or degradation of the matrix, they can be suspended with the cell suspension, they can be incorporated into microspheres which are suspended with the cells or attached to or incorporated within the matrix, or some combination thereof. Microspheres would typically be formed of materials similar to those forming the matrix, selected for their release properties rather than structural properties. Release properties can also be determined by the size and physical characteristics of the microspheres.
II. Cells to Be Implanted
Cells to be implanted are dissociated using standard techniques such as digestion with a collagenase, trypsin or other protease solution. Preferred cell types are mesenchymal cells, especially smooth or skeletal muscle cells, myocytes (muscle stem cells), fibroblasts, chondrocytes, adipocytes, fibromyoblasts, and ectodermal cells, including ductile and skin cells, hepatocytes, Islet cells, cells present in the intestine, and other parenchymal cells, osteoblasts and other cells forming bone or cartilage. In some cases it may also be desirable to include nerve cells. Cells can be normal or genetically engineered to provide additional or normal function. Methods for genetically engineering cells with retroviral vectors, polyethylene glycol, or other methods known to those skilled in the art can be used.
Cells are preferably autologous cells, obtained by biopsy and expanded in culture, although cells from close relatives or other donors of the same species may be used with appropriate immunosuppression. Immunologically inert cells, such as embryonic or fetal cells, stem cells, and cells genetically engineered to avoid the need for immunosuppression can also be used. Methods and drugs for immunosuppression are known to those skilled in the art of transplantation. A preferred compound is cyclosporin using the recommended dosages.
In the preferred embodiment, cells are obtained by biopsy and expanded in culture for subsequent implantation. Cells can be easily obtained through a biopsy anywhere in the body, for example, skeletal muscle biopsies can be obtained easily from the arm, forearm, or lower extremities, and smooth muscle can be obtained from the area adjacent to the subcutaneous tissue throughout the body. To obtain either type of muscle, the area to be biopsied can be locally anesthetized with a small amount of lidocaine injected subcutaneously. Alternatively, a small patch of lidocaine jelly can be applied over the area to be biopsied and left in place for a period of 5 to 20 minutes, prior to obtaining biopsy specimen. The biopsy can be effortlessly obtained with the use of a biopsy needle, a rapid action needle which makes the procedure extremely simple and almost painless. With the addition of the anesthetic agent, the procedure would be entirely painless. This small biopsy core of either skeletal or smooth muscle can then be transferred to media consisting of phosphate buffered saline. The biopsy specimen is then transferred to the lab where the muscle can be grown utilizing the explant technique, wherein the muscle is divided into very pieces which are adhered to culture plate, and serum containing media is added. Alternatively, the muscle biopsy can be enzymatically digested with agents such as trypsin and the cells dispersed in a culture plate with any of the routinely used medias. After cell expansion within the culture plate, the cells can be easily passaged utilizing the usual technique until an adequate number of cells is achieved.
III. Methods for Implantation
Unlike other prior art methods for making implantable matrices, the present method uses the recipient or an animal as the initial bioreactor to form a fibrous tissue-polymeric construct which optionally can be seeded with other cells and implanted. The matrix becomes infiltrated with fibrous tissue and/or blood vessels over a period ranging from between one day and a few weeks, most preferably one and two weeks. The matrix is then removed and implanted at the site where it is needed.
In one embodiment, the matrix is formed of polymer fibers having a particular desired shape, that is implanted subcutaneously. The implant is retrieved surgically, then one or more defined cell types distributed onto and into the fibers. In a second embodiment, the matrix is seeded with cells of a defined type, implanted until fibrous tissue has grown into the matrix, then the matrix removed, optionally cultured further in vitro, then reimplanted at a desired site.
The resulting structures are dictated by the matrix construction, including architecture, porosity (% void volume and pore diameter), polymer nature including composition, crystallinity, molecular weight, and degradability, hydrophobicity, and the inclusion of other biologically active molecules.
This methodology is particularly well suited for the construction of valves and tubular structures. Examples of valves are heart valves and valves of the type used for ventricular shunts for treatment of hydrocephaly. A similar structure could be used for an ascites shunt in the abdomen where needed due to liver disease or in the case of a lymphatic obstructive disease. Examples of tubular structures include blood vessels, intestine, ureters, and fallopian tubes.
The structures are formed at a site other than where they are ultimately required. This is particularly important in the case of tubular structures and valves, where integrity to fluid is essential, and where the structure is subjected to repeated stress and strain.
The present invention will be further understood by reference to the following non-limiting examples.
Tissue Engineering of Heart Valves
Valvular heart disease is a significant cause of morbidity and mortality. Construction of a tissue engineered valve using living autologous cells offers advantages over currently used mechanical or glutaraldehyde fixed xenograft valves.
Methods and Materials
A tissue engineered valve was constructed by seeding a synthetic polyglycolic acid (PGA) fiber based matrix with dissociated fibroblasts and endothelial cells harvested from a donor sheep heart valve. The cells were grown to confluence and split several times to increase the cell number. A mixed cell population including myofibroblasts and endothelial cells was obtained. The endothelial cells were labeled with an Ac-Dil-LDL fluorescent antibody obtained from a commercial source and sorted in a cell-sorting machine to yield a nearly pure endothelial cell population (LDL+) and a mixed cell population containing myofibroblasts and endothelial cells (LDL−). A PGA mesh (density 76.9 mg/ml and thickness 0.68 mm) was seeded with the mixed cell population and grown in culture. When the myofibroblasts reached confluence, endothelial cells were seeded onto the surface of the fibroblast/mesh constructs and grown into a single monolayer.
Immunohistochemical evaluation of constructs with antibodies against factor VIII, a specific marker for endothelial cells, revealed that tissue engineered valves histologically resemble native valve tissue. The effects of physiological flow on elastin and collagen production within the ECM were examined in a bioreactor and implanted in a sheep to determine if the constructs had the required pliability and mechanical strength for use in patients.
Tissue Engineering of Vascular Structures
Vascular smooth muscle tubular structures using a biodegradable polyglycolic acid polymer scaffold have been developed. The technique involves the isolation and culture of vascular smooth muscle cells, the reconstruction of a vascular wall using biodegradable polymer, and formation of the neo-tissue tubes in vitro. The feasibility of engineering vascular structures by coculturing endothelial cells with fibroblasts and smooth muscle cells on a synthetic biodegradable matrix in order to create tubular constructs which histologically resemble native vascular structures was also demonstrated.
Methods
In a first set of studies, bovine and ovine endothelial cells, smooth muscle cells, and fibroblasts were isolated using a combination of standard techniques including collagenase digestion and explantation. These cells were then expanded in tissue culture. All cells were grown in Delbecco's modified Eagle's media supplemented with 10% fetal bovine serum, 1% antibiotic solution, and basic fibroblast growth factor. Mixed colonies were purified using dilutional cloning. Thirty (N=30) two by two centimeter polyglycolic acid (PGA) fiber meshes (thickness=0.68 mm, density=76.9 mg/cc) were then serially seeded with 5×105 fibroblasts and smooth muscle cells and placed in culture. Five (N=5) 85% PGA, 15% polylatic acid tubular constructs (length=2 cm, diameter=0.8 cm) were seeded in a similar fashion. After the fibroblasts and smooth muscle cell constructs had grown to confluence (mean time 3 weeks), 1×106 endothelial cells were seeded onto them and they were placed in culture for one week. These vascular constructs were then fixed in a paraffin, sectioned and analyzed using immunohistochemical staining for factor VIII (specific for endothelial cells) and desmin (specific for muscle cells).
In a second set of studies, smooth muscle cells were obtained by harvesting the media from the artery of a lamb using standard explant techniques. Cells were expanded in culture through repeated passages and then seeded on the biodegradable polymer scaffold at a density of 1×106 cells per cm2 of polymer. The cell-polymer constructs were formed into tubes with internal diameters ranging from 2 mm to 5 mm and maintained in vitro for 6 to 8 weeks.
Results
Microscopic examination of all constructs in the first study (N=30/N=5) revealed that both types of constructs had achieved the proper histological architecture and resembled native vessels after one week. Immunohistochemical staining confirmed that endothelially lined smooth muscle/fibroblast tubes had been created. The extracellular matrices (ECM) of the vascular constructs were examined in order to determine the composition of elastin and collagen types I and III, the ECM molecules which determine the physical characteristics of native vascular tissues.
The results of the second study show that vascular smooth muscle tubes which retain their structure can be successfully formed using a polyglycolic acid polymer scaffold. The biodegradable polymer was absorbed over time, leaving a neo-tissue vascular smooth muscle tube.
Engineered bone from PGA Polymer Scaffold and Periosteum
The ability to create bone from periosteum and biodegradable polymer may have significant utility in reconstructive orthopedic and plastic surgery. Polyglycolic acid (PGA) is a preferred material for forming a biodegradable matrix which can be configured to a desirable shape and structure. This study was conducted to determine whether new bone constructs can be formed from periosteum or periosteal cells placed onto PGA polymer.
Materials and Methods
Bovine periosteum, harvested from fresh calf limbs, was placed either directly onto PGA polymer (1×1 cm) or onto tissue culture dishes for periosteal cell isolation. The periosteum/PGA construct was cultured for one week in MEM 199 culture media with antibiotics and ascorbic acid, then implanted into the dorsal subcutaneous space of nude mice. Periosteal cell, cultured from pieces of periosteum for two weeks, were isolated into cell suspension and seeded (approximately 1 to 3×107 cells) onto PGA polymer (1 ×1 cm); after one week in culture, the periosteal cell seeded polymer was implanted into the subcutaneous space of nude mice. Specimens, harvested at 4, 8, and 14 week intervals, were evaluated grossly and histologically.
Results
The periosteum/PGA constructs showed an organized cartilage matrix with early evidence of bone formation at four weeks, a mixture of bone and cartilage at 8 weeks, and a complete bone matrix at 14 weeks. Constructs created from periosteal cells seeded onto polymer showed presence of disorganized cartilage at 4 and 8 weeks, and a mixture of bone and cartilage at 14 weeks. Periosteum placed directly onto polymer will form an organized cartilage and bone matrix earlier than constructs formed from periosteal cell seeded polymer. This data indicates that PGA is an effective scaffold for periosteal cell attachment and migration to produce bone, which may offer new approaches to reconstructive surgery.
Bone Reconstruction with Tissue Engineered Vascularized Bone
The aim of this study was to determine if new vascularized bone could be engineered by transplantation of osteoblast around existing vascular pedicle using biodegradable polymers as cell delivery devices, to be used to reconstruct weight bearing bony defects.
Methods
Osteoblast and chondryocytes were isolated from calf periosteum and articular cartilage, cultured in vitro for three weeks, then seeded onto a 1×1 cm non-woven polyglycolic acid (PGA) mesh. After maintenance in vitro for one week, cell-polymer constructs were wrapped around saphenous vessels, and implanted into athymic rats for 8 weeks. The implants showed gross and histological evidence of vascularized bone or cartilage. At this time, bilateral 0.8 cm femoral shaft defect were created in the same rat, and fixed in position with a 3 cm craniofacial titanium miniplate. The new engineered bone/cartilage construct was then transferred to the femoral defect on its bilateral vascular pedicle. A total of 30 femoral defects were repaired in three groups of animals (each group composed of five animals with defects). Animals in Group 1 received implants composed of vascularized bone constructs, animals in Group 2 with vascular cartilage constructs, and Group 3 animals with blank polymer only.
At six months after surgery, the animals were studied radiographically for evidence of new bone formation at the site of the defect. Euthanasia was then performed by anesthetic overdose and each experimented femur was removed. Gross appearance was recorded and histological studies performed using hematoxylin and eosin (H & E) staining.
Results
Group 1 defect showed evidence of new bone formation around the defect. Neither Group 2 nor Group 3 defect showed any radiographic evidence of healing or bone formation. Grossly, Group 1 animals developed exuberant bony callus formation and healing of the defect. The animals in Group 2 showed filling of the bony defect with cartilaginous tissue, whereas all of the animals in Group 3 either developed a fibrous non-union or simple separation of both bony fragments with soft tissue invasion of the defect. The histological studies showed new bone formation in all Group 1 animals, new cartilage formation in all Group 2 animals, and fibrous tissue invasion in all Group 3 animals.
Conclusion
In conclusion, it was possible to engineer vascularized bone and cartilage grafts, which could be used to repair bone defects in the rat femur. Engineered tissue maintained the characteristics of the tissues form which the cells were originally isolated.
Engineering of Composite Bone and Cartilage
The ability to construct a composite structure of bone and cartilage offers a significant modality in reconstructive plastic and orthopedic surgery. The following study was conducted to engineer a bone and cartilage composite structure using periosteum, chondrocytes and biodegradable polymer and to direct bone and cartilage formation by selectively placing periosteum and chondrocytes onto the polymer scaffold.
Methods and materials
Bovine periosteum and cartilage were harvested from newborn calf limbs. Periosteum (1.5×2.0 cm) was wrapped around a polyglycolic acid/poly L-lactic acid co-polymer tube (3 cm in length, 3 mm in diameter), leaving the ends exposed. The cartilage pieces were enzymatically digested with collagenase, and chondrocytes (2×107 cells) were seeded onto each end of the exposed polymer. The composite construct was cultured for seven days in Medium 199 with antibiotics, fetal bovine serum, and ascorbic acid at 37° C. with 5% CO2. Eight constructs were then implanted into the dorsal subcutaneous space of eight nude mice. After 8 to 14 weeks in vivo, the implants were harvested and evaluated grossly and histologically.
Results
All implants formed into cylindrical shapes, flattened at the ends. The central portion of the implant formed into a bony matrix and the ends of the specimens formed into cartilage, approximately where the periosteum and chondrocytes were placed. Histological sections showed an organized matrix of bone and cartilage with a distinct transition between bone and cartilage.
Conclusions
The results show that periosteum and chondrocytes placed onto a biodegradable polymer will form into a composite tissue of bone and cartilage. Moreoever, bone and cartilage composite formation with selective placement of periosteum and chondrocytes on a biodegradable polymer scaffold was shown.
Implantation of Matrix for Ingrowth of Fibrous Tissue to Increase Mechanical Properties and Cell Survival
The following study was conducted to increase the mechanical strength and pliability of the heart valve leaflets or other engineered tissues such as those for use as blood vessels.
Methods
A PGA mesh as described in Example 1 or 2 was implanted subcutaneously in an animal, then removed after a period of one to two weeks. Fibroblasts migrated into the polymeric mesh while it was implanted. The implant was then seeded with other cells such as chondrocytes or endothelial cells and cultured in vitro for an additional period of time.
Results
The resulting implant was shown to have greater mechanical strength and pliability than implants formed solely by seeding of dissociated cells.
Modifications and variations of the method and compositions described herein will be obvious to those skilled in the art from the foregoing detailed description. Such modifications and variations are intended to come within the scope of the appended claims.
Claims (18)
1. A method for making a cell-matrix construct for use as a heart valve or blood vessel comprising
implanting into an animal at a first site a fibrous matrix formed of a synthetic biodegradable polymer having seeded therein a mixture of cells selected from the group selected from endothelial cells, myofibroblasts, skeletal muscle cells, vascular smooth muscle cells, myocytes, fibromyoblasts, and ectodermal cells, wherein the matrix is formed of a biocompatible, biodegradable polymer, and
implanting into an animal or human the matrix at a site where the resulting cell-construct is needed.
2. The method of claim 1 further comprising seeding the matrix with dissociated parenchymal or connective tissue cells.
3. The method of claim 1 wherein the matrix is first cultured at a first site in a patient prior to being implanted at a second site.
4. The method of claim 1 wherein the matrix is a heart valve and is implanted in the heart.
5. The method of claim 1 wherein the cell-matrix construct is seeded with vascular smooth muscle cells and endothelial cells is implanted to form a valve.
6. The method of claim 5 wherein the valve is a heart valve.
7. The method of claim 1 wherein the cell-matrix construct is seeded with endothelial cells and implanted to form a blood vessel.
8. A cell-matrix construct for use as a heart valve or heart valve leaflet construct consisting of
(a) a fibrous polymeric matrix consisting of a synthetic, biocompatible, chemically biodegradable polymer in the shape of a heart valve or heart valve leaflet,
(b) cells selected from the group consisting of endothelial cells, myofibroblasts, skeletal muscle cells, vascular smooth muscle cells, myocytes, fibromyoblasts, and ectodermal cells,
wherein the synthetic, biocompatible chemically biodegradable polymer provides the biomechanical properties of a heart valve or leaflet until the seeded cells can lay down their own extracellular matrix, and
the matrix is formed so that the cells can attach to and proliferate in a three dimensional space, to the edges of the matrix.
9. The cell-matrix construct of claim 8 comprising myofibroblasts grown to confluence and then endothelial cells seeded thereon.
10. The cell-matrix construct of claim 8 wherein the cell-matrix construct can withstand repeated stress and strain.
11. The cell-matrix construct of claim 8 wherein the cell-matrix construct is formed of a polymer selected from the group consisting of poly(lactide) (PLA), poly(glycolic acid) (PGA), poly(lactide-co-glycolide) (PLGA), poly(caprolactone), polyanhydrides, polyamino acids, and polyortho esters.
12. The cell-matrix construct of claim 8 wherein the cell-matrix construct contains interconnected pores in the range of between approximately 100 and 300 microns.
13. The cell-matrix construct of claim 8 wherein the cell-matrix construct includes growth factors.
14. The cell-matrix construct of claim 13 wherein the growth factors are selected from the group consisting of heparin binding growth factor (hbgf), transforming growth factor alpha or beta (TGFβ), alpha fibroblastic growth factor (FGF), epidermal growth factor (TGF), vascular endothelium growth factor (VEGF), insulin, glucagon, estrogen, nerve growth factor (NGF) and muscle morphogenic factor (MMP).
15. The cell-matrix construct of claim 8 wherein the cell-matrix further comprises bioactive factors incorporated to between one and 30% by weight.
16. The cell-matrix construct of claim 8 wherein the cell-matrix is first cultured in a bioreactor to form a fibrous tissue-polymeric construct before implantation.
17. The cell-matrix construct of claim 16 wherein the bioreactor is an animal.
18. A cell-matrix construct for implantation comprising a fibrous matrix formed of a synthetic biodegradable polymer having seeded therein a mixture of cells selected from the group consisting of endothelial cells, myofibroblasts, skeletal muscle cells, vascular smooth muscle cells, myocytes, fibromyoblasts, and ectodermal cells, wherein the matrix incorporates one or more struts or support members, cultured in vivo to form tissue, for implantation into a second second site in an animal or human.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/529,691 USRE42575E1 (en) | 1995-05-19 | 2006-09-28 | Engineering of strong, pliable tissues |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/445,280 US5855610A (en) | 1995-05-19 | 1995-05-19 | Engineering of strong, pliable tissues |
US09/185,360 US6348069B1 (en) | 1995-05-19 | 1998-11-03 | Engineering of strong, pliable tissues |
US10/782,750 USRE42479E1 (en) | 1995-05-19 | 2004-02-19 | Engineering of strong, pliable tissues |
US11/529,691 USRE42575E1 (en) | 1995-05-19 | 2006-09-28 | Engineering of strong, pliable tissues |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/185,360 Reissue US6348069B1 (en) | 1995-05-19 | 1998-11-03 | Engineering of strong, pliable tissues |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE42575E1 true USRE42575E1 (en) | 2011-07-26 |
Family
ID=23768289
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/445,280 Expired - Lifetime US5855610A (en) | 1995-05-19 | 1995-05-19 | Engineering of strong, pliable tissues |
US09/185,360 Ceased US6348069B1 (en) | 1995-05-19 | 1998-11-03 | Engineering of strong, pliable tissues |
US10/782,750 Expired - Lifetime USRE42479E1 (en) | 1995-05-19 | 2004-02-19 | Engineering of strong, pliable tissues |
US11/529,691 Expired - Lifetime USRE42575E1 (en) | 1995-05-19 | 2006-09-28 | Engineering of strong, pliable tissues |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/445,280 Expired - Lifetime US5855610A (en) | 1995-05-19 | 1995-05-19 | Engineering of strong, pliable tissues |
US09/185,360 Ceased US6348069B1 (en) | 1995-05-19 | 1998-11-03 | Engineering of strong, pliable tissues |
US10/782,750 Expired - Lifetime USRE42479E1 (en) | 1995-05-19 | 2004-02-19 | Engineering of strong, pliable tissues |
Country Status (1)
Country | Link |
---|---|
US (4) | US5855610A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100222882A1 (en) * | 2009-02-27 | 2010-09-02 | Badylak Stephen F | Joint bioscaffolds |
US9801910B2 (en) | 2014-03-17 | 2017-10-31 | Ethicon, Inc. | Decellularized pleural matrix |
Families Citing this family (185)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030086975A1 (en) * | 2001-11-08 | 2003-05-08 | Timothy Ringeisen | Method for making a porous Polymeric material |
US6528483B2 (en) | 1995-06-07 | 2003-03-04 | André Beaulieu | Method of producing concentrated non-buffered solutions of fibronectin |
US20030008396A1 (en) * | 1999-03-17 | 2003-01-09 | Ku David N. | Poly(vinyl alcohol) hydrogel |
US7524335B2 (en) * | 1997-05-30 | 2009-04-28 | Smith & Nephew, Inc. | Fiber-reinforced, porous, biodegradable implant device |
US5980564A (en) * | 1997-08-01 | 1999-11-09 | Schneider (Usa) Inc. | Bioabsorbable implantable endoprosthesis with reservoir |
WO1999022781A2 (en) * | 1997-10-31 | 1999-05-14 | Children's Medical Center Corporation | Bladder reconstruction |
US6872387B1 (en) | 1998-02-24 | 2005-03-29 | The Regents Of The University Of Michigan | Three-dimensional hydrogel/cell system |
US6660301B1 (en) | 1998-03-06 | 2003-12-09 | Biosphere Medical, Inc. | Injectable microspheres for dermal augmentation and tissue bulking |
US6171610B1 (en) * | 1998-04-24 | 2001-01-09 | University Of Massachusetts | Guided development and support of hydrogel-cell compositions |
US6027744A (en) * | 1998-04-24 | 2000-02-22 | University Of Massachusetts Medical Center | Guided development and support of hydrogel-cell compositions |
US20100030340A1 (en) * | 1998-06-30 | 2010-02-04 | Wolfinbarger Jr Lloyd | Plasticized Grafts and Methods of Making and Using Same |
US6293970B1 (en) | 1998-06-30 | 2001-09-25 | Lifenet | Plasticized bone and soft tissue grafts and methods of making and using same |
US8563232B2 (en) | 2000-09-12 | 2013-10-22 | Lifenet Health | Process for devitalizing soft-tissue engineered medical implants, and devitalized soft-tissue medical implants produced |
US20080077251A1 (en) * | 1999-06-07 | 2008-03-27 | Chen Silvia S | Cleaning and devitalization of cartilage |
US6551355B1 (en) * | 1998-08-14 | 2003-04-22 | Cambridge Scientific, Inc. | Tissue transplant coated with biocompatible biodegradable polymer |
US7001746B1 (en) | 1999-01-29 | 2006-02-21 | Artecel Sciences, Inc. | Methods and compositions for the differentiation of human preadipocytes into adipocytes |
DE19919625C2 (en) * | 1999-04-29 | 2002-10-31 | Symetis Ag Zuerich | In vitro method for producing a homologous heart valve and valve that can be produced by this method |
GB9910377D0 (en) * | 1999-05-05 | 1999-06-30 | Univ Westminster | Tissue engineering |
US20040167634A1 (en) * | 1999-05-26 | 2004-08-26 | Anthony Atala | Prosthetic kidney and its use for treating kidney disease |
CA2852534A1 (en) | 1999-08-05 | 2001-02-15 | Abt Holding Company | Multipotent adult stem cells and methods for isolation |
JP3603179B2 (en) * | 1999-09-09 | 2004-12-22 | グンゼ株式会社 | Cardiovascular tissue culture substrate and tissue regeneration method |
AU6132700A (en) * | 1999-09-30 | 2001-04-05 | Chienna B.V. | Polymers loaded with bioactive agents |
US6391049B1 (en) | 1999-10-06 | 2002-05-21 | Board Of Regents The University Of Texas System | Solid biodegradable device for use in tissue repair |
JP2001120582A (en) | 1999-10-22 | 2001-05-08 | Gunze Ltd | Artificial cardiac valve and method of manufacturing the same |
EP1099443A1 (en) * | 1999-11-11 | 2001-05-16 | Sulzer Orthopedics Ltd. | Transplant/implant device and method for its production |
DE19959750C1 (en) * | 1999-12-11 | 2001-05-31 | Axel Thierauf | Production of skin implant, e.g. for treating burn or other open wound, uses flat element of fine biocompatible, biodegradable or bioresorbable fibers of hydrolytically condensed silicon compound on nutrient solution |
US6428802B1 (en) | 1999-12-29 | 2002-08-06 | Children's Medical Center Corp. | Preparing artificial organs by forming polylayers of different cell populations on a substrate |
US6479064B1 (en) | 1999-12-29 | 2002-11-12 | Children's Medical Center Corporation | Culturing different cell populations on a decellularized natural biostructure for organ reconstruction |
US6376244B1 (en) * | 1999-12-29 | 2002-04-23 | Children's Medical Center Corporation | Methods and compositions for organ decellularization |
US6368859B1 (en) | 1999-12-29 | 2002-04-09 | Children's Medical Center Corporation | Methods and compositions for producing a fascial sling |
US7560275B2 (en) * | 1999-12-30 | 2009-07-14 | Vbi Technologies, L.L.C. | Compositions and methods for generating skin |
US7575921B2 (en) * | 1999-12-30 | 2009-08-18 | Vbi Technologies, L.L.C. | Spore-like cells and uses thereof |
EP1918366A1 (en) | 2000-02-26 | 2008-05-07 | Artecel, Inc. | Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof |
SG134168A1 (en) * | 2000-02-26 | 2007-08-29 | Artecel Sciences Inc | Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof |
US7582292B2 (en) | 2000-02-26 | 2009-09-01 | Artecel, Inc. | Adipose tissue derived stromal cells for the treatment of neurological disorders |
US7338657B2 (en) * | 2001-03-15 | 2008-03-04 | Biosphere Medical, Inc. | Injectable microspheres for tissue construction |
EP1274472A2 (en) | 2000-03-20 | 2003-01-15 | Biosphere Medical, Inc. | Injectable and swellable microspheres for tissue bulking |
US6436424B1 (en) | 2000-03-20 | 2002-08-20 | Biosphere Medical, Inc. | Injectable and swellable microspheres for dermal augmentation |
US20030212022A1 (en) * | 2001-03-23 | 2003-11-13 | Jean-Marie Vogel | Compositions and methods for gene therapy |
US8697137B2 (en) | 2000-03-24 | 2014-04-15 | Biosphere Medical, Inc. | Methods of using microspheres for active embolization |
US20020133229A1 (en) | 2000-03-24 | 2002-09-19 | Laurencin Cato T. | Ligament and tendon replacement constructs and methods for production and use thereof |
US6652583B2 (en) * | 2000-04-07 | 2003-11-25 | Rhode Island Hospital | Cardiac valve replacement |
ES2288946T3 (en) * | 2000-04-14 | 2008-02-01 | University Of Pittsburgh | INCREASE AND ABULTING OF SOFT TISSUE AND BONE USING PROGENITOR CELLS DERIVED FROM MUSCLE, ITS COMPOSITIONS AND TREATMENTS. |
GB0011244D0 (en) * | 2000-05-11 | 2000-06-28 | Smith & Nephew Inc | Tissue regrafting |
US7108721B2 (en) * | 2000-05-11 | 2006-09-19 | Massachusetts Institute Of Technology | Tissue regrafting |
DE10026480A1 (en) * | 2000-05-29 | 2001-12-13 | Augustinus Bader | Method of making a recipient-specific tissue graft or implant |
DE10026482A1 (en) * | 2000-05-29 | 2001-12-13 | Augustinus Bader | Process for the production of a bioartificial graft |
US6942873B2 (en) | 2000-09-25 | 2005-09-13 | The Board Of Trustees Of The University Of Illinois | Microfabrication of membranes containing projections and grooves for growing cells |
WO2002057428A1 (en) * | 2000-10-30 | 2002-07-25 | University Of Massachusetts | Isolation of spore-like cells from tissues exposed to extreme conditions |
US6835390B1 (en) * | 2000-11-17 | 2004-12-28 | Jon Vein | Method for producing tissue engineered meat for consumption |
US6696074B2 (en) * | 2000-12-04 | 2004-02-24 | Tei Biosciences, Inc. | Processing fetal or neo-natal tissue to produce a scaffold for tissue engineering |
US6669725B2 (en) | 2000-12-28 | 2003-12-30 | Centerpulse Biologics Inc. | Annuloplasty ring for regeneration of diseased or damaged heart valve annulus |
US6899873B2 (en) * | 2001-02-02 | 2005-05-31 | The Regents Of The University Of Michigan | Method of forming micro-tubular polymeric materials |
EP1230939B2 (en) * | 2001-02-13 | 2011-01-19 | corLife GbR | Bioartificial vascularised tissue matrix and bioartificial vascularised tissue |
US7326564B2 (en) | 2001-02-20 | 2008-02-05 | St. Jude Medical, Inc. | Flow system for medical device evaluation and production |
JP4680483B2 (en) * | 2001-02-23 | 2011-05-11 | ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | Rapid preparation of stem cell matrix for use in the treatment and repair of tissues and organs |
DK2105497T3 (en) | 2001-04-24 | 2019-06-24 | Dolores Baksh | Progenitor cell populations, their expansion, and growth of non-hematopoietic cell types and tissues therefrom |
US6913762B2 (en) * | 2001-04-25 | 2005-07-05 | Mayo Foundation For Medical Education And Research | Stent having non-woven framework containing cells |
US20030129751A1 (en) * | 2001-05-16 | 2003-07-10 | Grikscheit Tracy C. | Tissue-engineered organs |
DE10126137C1 (en) * | 2001-05-29 | 2002-11-07 | Andreas Haisch | In vitro preparation of cells, tissues and organs, useful e.g. as wound dressing, as model or implant, by growing on resorbable matrix of hydrolyzed silane |
WO2002102237A2 (en) * | 2001-06-15 | 2002-12-27 | The Cleveland Clinic Foundation | Tissue engineered mitral valve chrodae and methods of making and using same |
US8025896B2 (en) * | 2001-07-16 | 2011-09-27 | Depuy Products, Inc. | Porous extracellular matrix scaffold and method |
EP1406561A4 (en) * | 2001-07-16 | 2008-03-12 | Edwards Lifesciences Corp | Tissue engineered heart valve |
US7819918B2 (en) * | 2001-07-16 | 2010-10-26 | Depuy Products, Inc. | Implantable tissue repair device |
US8012205B2 (en) * | 2001-07-16 | 2011-09-06 | Depuy Products, Inc. | Cartilage repair and regeneration device |
EP1416874A4 (en) * | 2001-07-16 | 2007-04-18 | Depuy Products Inc | Hybrid biologic/synthetic porous extracellular matrix scaffolds |
AU2002354911B2 (en) | 2001-07-16 | 2007-08-30 | Depuy Products, Inc. | Meniscus regeneration device and method |
US20030032961A1 (en) * | 2001-07-16 | 2003-02-13 | Pelo Mark Joseph | Devices from naturally occurring biologically derived materials |
EP1416879A4 (en) * | 2001-07-16 | 2007-04-25 | Depuy Products Inc | Unitary surgical device and method |
JP2005509495A (en) * | 2001-11-16 | 2005-04-14 | チルドレンズ メディカル センター コーポレーション | Enhancement of organ function |
DE60239217D1 (en) * | 2001-11-16 | 2011-03-31 | Childrens Medical Center | GENERATION OF WOVEN TECHNOLOGY MANUFACTURED FEMALE REPRODUCTIVE ORGANS |
US7504258B2 (en) * | 2001-12-11 | 2009-03-17 | Cytograft Tissue Engineering, Inc. | Tissue engineered cellular sheets, methods of making and use thereof |
US7297540B2 (en) * | 2002-01-15 | 2007-11-20 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods of generating tissue using devitalized, acellular scaffold matrices derived from micro-organs |
AU2003219916A1 (en) * | 2002-02-22 | 2003-09-09 | University Of Washington | Bioengineered tissue substitutes |
US20050260259A1 (en) * | 2004-04-23 | 2005-11-24 | Bolotin Elijah M | Compositions for treatment with glucagon-like peptide, and methods of making and using the same |
WO2003072143A1 (en) * | 2002-02-27 | 2003-09-04 | Pharmain, Ltd. | Compositions for delivery of therapeutics and other materials, and methods of making and using the same |
US7635463B2 (en) * | 2002-02-27 | 2009-12-22 | Pharmain Corporation | Compositions for delivery of therapeutics and other materials |
US7396537B1 (en) * | 2002-02-28 | 2008-07-08 | The Trustees Of The University Of Pennsylvania | Cell delivery patch for myocardial tissue engineering |
US20040254640A1 (en) * | 2002-03-01 | 2004-12-16 | Children's Medical Center Corporation | Needle punched textile for use in growing anatomical elements |
US7776600B2 (en) | 2002-04-18 | 2010-08-17 | Carnegie Mellon University | Method of manufacturing hydroxyapatite and uses therefor in delivery of nucleic acids |
AU2003218271A1 (en) * | 2002-04-18 | 2003-11-03 | Carnegie Mellon University | Method of manufacturing hydroxyapatite and uses therefor in delivery of nucleic acids |
KR100484636B1 (en) * | 2002-04-30 | 2005-04-20 | 경북대학교 산학협력단 | Matrix for cultivating hepatocyte |
US7299805B2 (en) | 2002-06-07 | 2007-11-27 | Marctec, Llc | Scaffold and method for implanting cells |
DE10235237A1 (en) * | 2002-08-01 | 2004-02-12 | Symetis Ag | In vitro preparation of homologous heart valves, useful for replacement of diseased valves, by inoculating biodegradable carrier with fibroblasts and attachment to a non-degradable stent |
AU2003284875A1 (en) * | 2002-10-17 | 2004-05-04 | Vacanti, Joseph P. | Biological scaffolding material |
KR100539371B1 (en) * | 2002-10-21 | 2005-12-27 | 메디칸(주) | In vitro cultured human preadipocyte for human soft tissue volume replacement with injectable material as a scaffold |
KR101504616B1 (en) * | 2002-10-29 | 2015-03-23 | 인스메드 인코포레이티드 | Sustained release of antiinfectives |
US7718189B2 (en) | 2002-10-29 | 2010-05-18 | Transave, Inc. | Sustained release of antiinfectives |
US7879351B2 (en) * | 2002-10-29 | 2011-02-01 | Transave, Inc. | High delivery rates for lipid based drug formulations, and methods of treatment thereof |
US7627373B2 (en) * | 2002-11-30 | 2009-12-01 | Cardiac Pacemakers, Inc. | Method and apparatus for cell and electrical therapy of living tissue |
US20040158289A1 (en) * | 2002-11-30 | 2004-08-12 | Girouard Steven D. | Method and apparatus for cell and electrical therapy of living tissue |
US8940292B2 (en) | 2003-01-28 | 2015-01-27 | Wake Forest University Health Sciences | Enhancement of angiogenesis to grafts using cells engineered to produce growth factors |
WO2004082524A2 (en) * | 2003-03-13 | 2004-09-30 | William Marsh Rice University | Composite injectable and pre-fabricated bone replacement material and method for the production of such bone replacement material |
WO2004093932A1 (en) * | 2003-04-21 | 2004-11-04 | Verigen Ag | A seeded tear resistant scaffold |
ES2354304T3 (en) * | 2003-04-25 | 2011-03-11 | The University Of Pittsburgh | CELLS DERIVED FROM THE MUSCLE (MDCS) TO PROMOTE AND POWER THE REGENERATION AND REPAIR OF NERVES. |
DE10322024A1 (en) * | 2003-05-16 | 2004-12-02 | Symetis Ag | Bioreactor for manufacturing a tissue prosthesis, in particular a heart valve |
WO2005010172A2 (en) * | 2003-07-16 | 2005-02-03 | Boston Scientific Limited | Aligned scaffolds for improved myocardial regeneration |
US20050013870A1 (en) * | 2003-07-17 | 2005-01-20 | Toby Freyman | Decellularized extracellular matrix of conditioned body tissues and uses thereof |
WO2007083504A1 (en) * | 2003-08-01 | 2007-07-26 | Norimasa Nakamura | Scaffold-free self-organized 3d synthetic tissue |
WO2005012512A1 (en) | 2003-08-01 | 2005-02-10 | Norimasa Nakamura | Scaffold-free self-organized 3d synthetic tissue |
US20070087959A1 (en) * | 2003-08-19 | 2007-04-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method of inducing biomineralization method of inducing bone regeneration and methods related thereof |
US7261732B2 (en) * | 2003-12-22 | 2007-08-28 | Henri Justino | Stent mounted valve |
CA2558661C (en) * | 2004-02-06 | 2012-09-04 | Georgia Tech Research Corporation | Load bearing biocompatible device |
WO2005077013A2 (en) | 2004-02-06 | 2005-08-25 | Georgia Tech Research Corporation | Surface directed cellular attachment |
US7840263B2 (en) * | 2004-02-27 | 2010-11-23 | Cardiac Pacemakers, Inc. | Method and apparatus for device controlled gene expression |
CA2557231C (en) | 2004-03-05 | 2013-12-31 | The Trustees Of Columbia University In The City Of New York | Multi-phased, biodegradable and osteointegrative composite scaffold for biological fixation of musculoskeletal soft tissue to bone |
US20060036331A1 (en) * | 2004-03-05 | 2006-02-16 | Lu Helen H | Polymer-ceramic-hydrogel composite scaffold for osteochondral repair |
US20050249772A1 (en) * | 2004-05-04 | 2005-11-10 | Prasanna Malaviya | Hybrid biologic-synthetic bioabsorbable scaffolds |
US7764995B2 (en) | 2004-06-07 | 2010-07-27 | Cardiac Pacemakers, Inc. | Method and apparatus to modulate cellular regeneration post myocardial infarct |
US20050278025A1 (en) * | 2004-06-10 | 2005-12-15 | Salumedica Llc | Meniscus prosthesis |
US7351423B2 (en) | 2004-09-01 | 2008-04-01 | Depuy Spine, Inc. | Musculo-skeletal implant having a bioactive gradient |
US20060097422A1 (en) * | 2004-11-08 | 2006-05-11 | Diamond Andrew J | Method for performing surgery and appliances produced thereby |
CA2881343A1 (en) * | 2004-12-08 | 2006-06-15 | Shire Regenerative Medicine, Inc. | Methods and compositions for enhancing vascular access |
US8060219B2 (en) * | 2004-12-20 | 2011-11-15 | Cardiac Pacemakers, Inc. | Epicardial patch including isolated extracellular matrix with pacing electrodes |
US7981065B2 (en) | 2004-12-20 | 2011-07-19 | Cardiac Pacemakers, Inc. | Lead electrode incorporating extracellular matrix |
US8874204B2 (en) * | 2004-12-20 | 2014-10-28 | Cardiac Pacemakers, Inc. | Implantable medical devices comprising isolated extracellular matrix |
US7354627B2 (en) * | 2004-12-22 | 2008-04-08 | Depuy Products, Inc. | Method for organizing the assembly of collagen fibers and compositions formed therefrom |
EP1693025A1 (en) * | 2005-02-17 | 2006-08-23 | Universität Zürich | Method of manufacturing a tissue-engineered prosthesis |
US8491457B2 (en) * | 2005-03-11 | 2013-07-23 | Wake Forest University Health Services | Tissue engineered blood vessels |
US20060204445A1 (en) * | 2005-03-11 | 2006-09-14 | Anthony Atala | Cell scaffold matrices with image contrast agents |
CA2602050C (en) | 2005-03-11 | 2013-12-03 | Wake Forest University Health Sciences | Production of tissue engineered heart valves |
US20060204539A1 (en) | 2005-03-11 | 2006-09-14 | Anthony Atala | Electrospun cell matrices |
WO2006099332A2 (en) | 2005-03-11 | 2006-09-21 | Wake Forest University Health Sciences | Production of tissue engineered digits and limbs |
DE602006014814D1 (en) * | 2005-04-21 | 2010-07-22 | Massachusetts Inst Technology | MATERIALS AND METHOD FOR CHANGING AN IMMUNE RESPONSE TO EXOGENOUS AND ENDOGENOUS IMMUNOGENES, INCLUDING GENIDENTIAL AND NON-GENIDENTIAL CELLS, TISSUE OR ORGANS |
CN104815331A (en) | 2005-05-09 | 2015-08-05 | 生物领域医疗公司 | Compositions and methods using microspheres and non-ionic contrast agents |
CN101878757A (en) | 2005-06-21 | 2010-11-10 | 渗透治疗有限公司 | Be used to strengthen the method and composition of vascular access |
SI1948259T1 (en) * | 2005-10-26 | 2017-07-31 | Genesis Technologies Limited | Acellular bioabsorbable tissue regeneration matrices produced by incubating acellular blood products |
US20070098798A1 (en) * | 2005-10-28 | 2007-05-03 | Medtronic, Inc. | Method and article to restore function to a flow control location in a patient |
US20100204783A1 (en) * | 2005-12-06 | 2010-08-12 | Helen Marie Nugent | Methods and compositions for enhancing vascular access |
PT1962805T (en) | 2005-12-08 | 2016-10-05 | Insmed Inc | Lipid-based compositions of antiinfectives for treating pulmonary infections |
CN101365490B (en) | 2005-12-19 | 2012-11-28 | 药明公司 | Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same |
US20070178137A1 (en) * | 2006-02-01 | 2007-08-02 | Toby Freyman | Local control of inflammation |
US20100092532A1 (en) * | 2006-11-07 | 2010-04-15 | Helen Marie Nugent | Materials and Methods for Treating and Managing Angiogenesis-Mediated Diseases |
US20100047309A1 (en) * | 2006-12-06 | 2010-02-25 | Lu Helen H | Graft collar and scaffold apparatuses for musculoskeletal tissue engineering and related methods |
US7871440B2 (en) * | 2006-12-11 | 2011-01-18 | Depuy Products, Inc. | Unitary surgical device and method |
US20080176206A1 (en) * | 2007-01-18 | 2008-07-24 | Toshiharu Shinoka | Cardiovascular tissue culture substrate |
US8753391B2 (en) | 2007-02-12 | 2014-06-17 | The Trustees Of Columbia University In The City Of New York | Fully synthetic implantable multi-phased scaffold |
US20100196455A1 (en) * | 2007-05-04 | 2010-08-05 | Transave, Inc. | Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof |
US9333214B2 (en) | 2007-05-07 | 2016-05-10 | Insmed Incorporated | Method for treating pulmonary disorders with liposomal amikacin formulations |
US9114081B2 (en) | 2007-05-07 | 2015-08-25 | Insmed Incorporated | Methods of treating pulmonary disorders with liposomal amikacin formulations |
US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
US9580688B2 (en) * | 2007-06-08 | 2017-02-28 | Wake Forest University Health Sciences | Kidney structures and methods of forming the same |
WO2008153970A1 (en) * | 2007-06-08 | 2008-12-18 | Wake Forest University Health Sciences | Selective cell therapy for the treatment of renal failure |
WO2008156705A1 (en) * | 2007-06-13 | 2008-12-24 | Pervasis Therapeutics, Inc. | Methods and devices for minimally-invasive delivery of cell-containing flowable compositions |
US9744043B2 (en) * | 2007-07-16 | 2017-08-29 | Lifenet Health | Crafting of cartilage |
US9125743B2 (en) * | 2007-07-16 | 2015-09-08 | Lifenet Health | Devitalization and recellularization of cartilage |
US7960336B2 (en) * | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
ES2475966T3 (en) | 2007-08-09 | 2014-07-11 | The Board Of Regents Of The University Of Texas System | Two-layer bone type brackets |
US8563527B2 (en) * | 2007-08-20 | 2013-10-22 | Pharmain Corporation | Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same |
WO2009042671A1 (en) * | 2007-09-24 | 2009-04-02 | The Board Of Trustees Of The University Of Illinois | Three-dimensional microfabricated bioreactors with embedded capillary network |
US20090176892A1 (en) * | 2008-01-09 | 2009-07-09 | Pharmain Corporation | Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same |
US11051733B2 (en) * | 2008-01-18 | 2021-07-06 | Wake Forest University Health Sciences | Isolating and purifying cells for therapy |
EP2254989A1 (en) * | 2008-02-14 | 2010-12-01 | The General Hospital Corporation | Well-based flow system for cell culture |
CA2734858C (en) * | 2008-08-18 | 2019-01-15 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Bone augmentation utilizing muscle-derived progenitor compositions in biocompatible matrix, and treatments thereof |
NZ593208A (en) * | 2008-11-04 | 2013-01-25 | Tengion Inc | Cell-scaffold constructs |
WO2010057013A1 (en) * | 2008-11-14 | 2010-05-20 | Wake Forest University Health Sciences | Selective cell therapy for the treatment of renal failure |
WO2010111278A1 (en) | 2009-03-23 | 2010-09-30 | The Texas A&M University System | Compositions of mesenchymal stem cells to regenerate bone |
DE102009032218A1 (en) * | 2009-07-06 | 2011-01-13 | Aesculap Aktiengesellschaft | Elevated implant for the reconstruction of meniscal defects or meniscal duodenal defects |
KR102081356B1 (en) | 2009-11-12 | 2020-02-25 | 브이셀 세라퓨틱스 인코포레이티드 | Subpopulations of spore-like cells and uses |
EP2566529B1 (en) * | 2010-05-03 | 2016-08-31 | RegenMed (Cayman) Ltd. | Smooth muscle cell constructs |
US9352003B1 (en) | 2010-05-14 | 2016-05-31 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US10130736B1 (en) | 2010-05-14 | 2018-11-20 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US8883210B1 (en) | 2010-05-14 | 2014-11-11 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US8834928B1 (en) | 2011-05-16 | 2014-09-16 | Musculoskeletal Transplant Foundation | Tissue-derived tissugenic implants, and methods of fabricating and using same |
CA2837303C (en) | 2011-05-26 | 2019-08-20 | Cartiva, Inc. | Tapered joint implant and related tools |
BR112014005752A2 (en) * | 2011-09-12 | 2017-03-28 | Organovo Inc | platform for implantable tissues and organs produced by tissue engineering and methods for their production |
WO2013074099A1 (en) | 2011-11-16 | 2013-05-23 | Empire Technology Development Llc | Three-dimensional porous biodegradable cell scaffold |
US9877822B2 (en) | 2012-04-24 | 2018-01-30 | Biostage, Inc. | Engineered tissue scaffolds and supports therefor |
KR102092361B1 (en) | 2012-05-21 | 2020-03-23 | 인스메드 인코포레이티드 | Systems for treating pulmonary infections |
BR112015012351A8 (en) | 2012-11-29 | 2019-10-01 | Insmed Inc | stabilized lipid glycopeptide antibiotic composition and use of a lipid component, a glycopeptide antibiotic component and an amino acid or derivative thereof |
US11284987B2 (en) | 2013-01-09 | 2022-03-29 | Biostage, Inc. | Synthetic scaffolds |
EP2983643A4 (en) | 2013-04-12 | 2016-12-28 | Univ Columbia | Methods for host cell homing and dental pulp regeneration |
CA2919374C (en) | 2013-07-30 | 2019-12-03 | Musculoskeletal Transplant Foundation | Acellular soft tissue-derived matrices and methods for preparing same |
US10092679B2 (en) | 2013-10-18 | 2018-10-09 | Wake Forest University Health Sciences | Laminous vascular constructs combining cell sheet engineering and electrospinning technologies |
CA2949078C (en) | 2014-05-15 | 2022-09-20 | Insmed Incorporated | Methods for treating pulmonary non-tuberculous mycobacterial infections |
DE102014008476A1 (en) | 2014-06-05 | 2015-12-17 | Michael Jagodzinski | Production of a Component for Cultivation of a Joint Surface Implant, Cultivation and Implantation of a Joint Surface Implant |
CN105983134A (en) * | 2015-03-05 | 2016-10-05 | 刘畅 | Artificial blood vessel and preparation method thereof |
WO2016161025A1 (en) | 2015-03-31 | 2016-10-06 | Cartiva, Inc. | Hydrogel implants with porous materials and methods |
EP3892241A1 (en) | 2015-03-31 | 2021-10-13 | Cartiva, Inc. | Drill bit for carpometacarpal implant |
AU2016248062B2 (en) | 2015-04-14 | 2020-01-23 | Cartiva, Inc. | Tooling for creating tapered opening in tissue and related methods |
US10531957B2 (en) | 2015-05-21 | 2020-01-14 | Musculoskeletal Transplant Foundation | Modified demineralized cortical bone fibers |
US10912864B2 (en) | 2015-07-24 | 2021-02-09 | Musculoskeletal Transplant Foundation | Acellular soft tissue-derived matrices and methods for preparing same |
US11052175B2 (en) | 2015-08-19 | 2021-07-06 | Musculoskeletal Transplant Foundation | Cartilage-derived implants and methods of making and using same |
MX2019015321A (en) * | 2017-06-16 | 2020-07-20 | Avery Therapeutics Inc | Three dimensional tissue compositions and methods of use. |
US11571386B2 (en) | 2018-03-30 | 2023-02-07 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
Citations (138)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1995970A (en) | 1931-04-04 | 1935-03-26 | Du Pont | Polymeric lactide resin |
US2609347A (en) | 1948-05-27 | 1952-09-02 | Wilson Christopher Lumley | Method of making expanded polyvinyl alcohol-formaldehyde reaction product and product resulting therefrom |
US2653917A (en) | 1950-06-15 | 1953-09-29 | Christopher L Wilson | Method of making an expanded material and the product resulting therefrom |
US2659935A (en) | 1950-03-18 | 1953-11-24 | Christopher L Wilson | Method of making compressed sponges |
US2664366A (en) | 1949-09-19 | 1953-12-29 | Wilson Christopher Lumley | Plasticized sponge material and method of making same |
US2676945A (en) | 1950-10-18 | 1954-04-27 | Du Pont | Condensation polymers of hydroxyacetic acid |
US2683136A (en) | 1950-10-25 | 1954-07-06 | Du Pont | Copolymers of hydroxyacetic acid with other alcohol acids |
US2703316A (en) | 1951-06-05 | 1955-03-01 | Du Pont | Polymers of high melting lactide |
US2758987A (en) | 1952-06-05 | 1956-08-14 | Du Pont | Optically active homopolymers containing but one antipodal species of an alpha-monohydroxy monocarboxylic acid |
US2846407A (en) | 1954-01-13 | 1958-08-05 | Wilson Christopher Lumley | Method of making a detergent and solvent resistant sponge material |
US2951828A (en) | 1957-03-04 | 1960-09-06 | Boehringer Sohn Ingelheim | Process for the production of bead polymerizates from cyclic internal esters of alpha-hydroxy carboxylic acids |
US3514791A (en) * | 1967-07-25 | 1970-06-02 | Charles H Sparks | Tissue grafts |
US3531561A (en) | 1965-04-20 | 1970-09-29 | Ethicon Inc | Suture preparation |
US3826241A (en) | 1972-10-16 | 1974-07-30 | Investors In Ventures Inc | Implanting method |
US3880991A (en) | 1969-03-24 | 1975-04-29 | Brook David E | Polymeric article for dispensing drugs |
US3883393A (en) | 1972-05-18 | 1975-05-13 | Us Health Education & Welfare | Cell culture on semi-permeable tubular membranes |
US3902497A (en) | 1974-03-25 | 1975-09-02 | American Cyanamid Co | Body absorbable sponge and method of making |
US3935065A (en) | 1971-09-02 | 1976-01-27 | Roland Karl Doerig | Procedure for conservation of living organs and apparatus for the execution of this procedure |
US3949073A (en) | 1974-11-18 | 1976-04-06 | The Board Of Trustees Of Leland Stanford Junior University | Process for augmenting connective mammalian tissue with in situ polymerizable native collagen solution |
US3960150A (en) | 1971-09-09 | 1976-06-01 | Alza Corporation | Bioerodible ocular device |
US3974526A (en) | 1973-07-06 | 1976-08-17 | Dardik Irving I | Vascular prostheses and process for producing the same |
US3992725A (en) | 1973-11-16 | 1976-11-23 | Homsy Charles A | Implantable material and appliances and method of stabilizing body implants |
US3995444A (en) | 1974-11-08 | 1976-12-07 | American Hospital Supply Corporation | Organ perfusion system |
US4026304A (en) | 1972-04-12 | 1977-05-31 | Hydro Med Sciences Inc. | Bone generating method and device |
US4060081A (en) | 1975-07-15 | 1977-11-29 | Massachusetts Institute Of Technology | Multilayer membrane useful as synthetic skin |
US4069307A (en) | 1970-10-01 | 1978-01-17 | Alza Corporation | Drug-delivery device comprising certain polymeric materials for controlled release of drug |
US4137921A (en) | 1977-06-24 | 1979-02-06 | Ethicon, Inc. | Addition copolymers of lactide and glycolide and method of preparation |
US4141087A (en) | 1977-01-19 | 1979-02-27 | Ethicon, Inc. | Isomorphic copolyoxalates and sutures thereof |
US4144126A (en) | 1975-05-21 | 1979-03-13 | Beecham Group Limited | Cell culture method |
DE2853614A1 (en) | 1978-01-25 | 1979-07-26 | Bentley Lab | IMPLANT |
US4186448A (en) | 1976-04-16 | 1980-02-05 | Brekke John H | Device and method for treating and healing a newly created bone void |
US4192827A (en) | 1974-06-27 | 1980-03-11 | Ciba-Geigy Corporation | Water-insoluble hydrophilic copolymers |
US4205399A (en) | 1977-06-13 | 1980-06-03 | Ethicon, Inc. | Synthetic absorbable surgical devices of poly(alkylene oxalates) |
US4228243A (en) | 1978-07-13 | 1980-10-14 | Toray Industries, Inc. | Cell culture propagation apparatus |
US4239664A (en) | 1978-10-31 | 1980-12-16 | Research Corporation | Anti-thrombogenic PVP-heparin polymer |
US4243775A (en) | 1978-11-13 | 1981-01-06 | American Cyanamid Company | Synthetic polyester surgical articles |
US4277582A (en) | 1978-03-03 | 1981-07-07 | Ciba-Geigy Corporation | Water-insoluble hydrophilic copolymers |
US4280954A (en) | 1975-07-15 | 1981-07-28 | Massachusetts Institute Of Technology | Crosslinked collagen-mucopolysaccharide composite materials |
US4304591A (en) | 1978-01-25 | 1981-12-08 | Ciba-Geigy Corporation | Water-insoluble hydrophilic copolymers used as carriers for medicaments and pesticides |
US4304866A (en) | 1979-11-14 | 1981-12-08 | Massachusetts Institute Of Technology | Transplantable sheets of living keratinous tissue |
US4328204A (en) | 1977-03-02 | 1982-05-04 | Ethicon, Inc. | Absorbable polymer-drug compounds and method for making same |
US4347847A (en) | 1980-06-06 | 1982-09-07 | Usher Francis C | Method of hernia repair |
US4348329A (en) | 1979-12-20 | 1982-09-07 | Dennis Chapman | Biocompatible surfaces |
US4352883A (en) | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
US4356261A (en) | 1980-04-22 | 1982-10-26 | Rush-Presbyterian-St. Luke's Medical Center | Anti-invasion factor containing cultures |
US4391797A (en) | 1977-01-05 | 1983-07-05 | The Children's Hospital Medical Center | Systems for the controlled release of macromolecules |
US4416986A (en) | 1981-01-16 | 1983-11-22 | Merck & Co., Inc. | Methods of producing HBsAg |
US4427808A (en) | 1980-07-21 | 1984-01-24 | Ceskoslovenska Akademie Ved | Composite polymeric material for biological and medical applications and the method for its preparation |
US4431428A (en) | 1981-09-30 | 1984-02-14 | Trimedyne, Inc. | Bio-artificial organ using microencapsulated enzymes |
US4438198A (en) | 1981-09-30 | 1984-03-20 | Trimedyne, Inc. | Biochemically active matrix for use in a bio-artificial organ |
US4439152A (en) | 1982-03-04 | 1984-03-27 | Small Irwin A | Method of jawbone abutment implant for dental prostheses and implant device |
US4440921A (en) | 1982-06-21 | 1984-04-03 | Research Corporation | Coupling of polyorganophosphazenes to carboxylic acid |
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4446234A (en) | 1981-10-23 | 1984-05-01 | The United States Of America As Represented By The Department Of Health And Human Services | Vitro cellular interaction with amnion membrane substrate |
US4446229A (en) | 1982-12-30 | 1984-05-01 | Indech Robert B | Method of tissue growth |
US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
US4456687A (en) | 1978-11-16 | 1984-06-26 | President And Fellows Of Harvard College | Agents for promoting growth of epithelial cells |
US4458678A (en) | 1981-10-26 | 1984-07-10 | Massachusetts Institute Of Technology | Cell-seeding procedures involving fibrous lattices |
US4485097A (en) | 1982-05-26 | 1984-11-27 | Massachusetts Institute Of Technology | Bone-equivalent and method for preparation thereof |
US4485096A (en) | 1982-02-26 | 1984-11-27 | Massachusetts Institute Of Technology | Tissue-equivalent and method for preparation thereof |
US4489056A (en) | 1982-06-30 | 1984-12-18 | Merck & Co., Inc. | Acid anhydrides as rate controlling agent for the erosion of polymers which latter polymers have beneficial substances dispersed throughout their matrix or where the polymer matrix surrounds the beneficial substance |
US4495174A (en) | 1982-06-21 | 1985-01-22 | Research Corporation | Anesthetic polyorganophosphazenes |
US4494385A (en) | 1982-06-04 | 1985-01-22 | Hoxan Corporation | Method of preserving organ and apparatus for preserving the same |
US4505266A (en) | 1981-10-26 | 1985-03-19 | Massachusetts Institute Of Technology | Method of using a fibrous lattice |
US4520821A (en) | 1982-04-30 | 1985-06-04 | The Regents Of The University Of California | Growing of long-term biological tissue correction structures in vivo |
US4528265A (en) | 1982-05-11 | 1985-07-09 | Becker Robert O | Processes and products involving cell modification |
US4544516A (en) | 1982-07-28 | 1985-10-01 | Battelle Development Corporation | Collagen orientation |
US4545082A (en) | 1982-03-25 | 1985-10-08 | Vascutek Limited | Vascular prosthesis |
US4553272A (en) | 1981-02-26 | 1985-11-19 | University Of Pittsburgh | Regeneration of living tissues by growth of isolated cells in porous implant and product thereof |
US4559298A (en) | 1982-11-23 | 1985-12-17 | American National Red Cross | Cryopreservation of biological materials in a non-frozen or vitreous state |
US4559304A (en) | 1982-08-09 | 1985-12-17 | Koken Co., Ltd. | Substratum for cell culture and a method for culturing and isolating cells using same |
US4563350A (en) | 1984-10-24 | 1986-01-07 | Collagen Corporation | Inductive collagen based bone repair preparations |
US4563489A (en) | 1984-02-10 | 1986-01-07 | University Of California | Biodegradable organic polymer delivery system for bone morphogenetic protein |
US4576608A (en) | 1980-11-06 | 1986-03-18 | Homsy Charles A | Porous body-implantable polytetrafluoroethylene |
US4595713A (en) | 1985-01-22 | 1986-06-17 | Hexcel Corporation | Medical putty for tissue augmentation |
US4609551A (en) | 1984-03-20 | 1986-09-02 | Arnold Caplan | Process of and material for stimulating growth of cartilage and bony tissue at anatomical sites |
DE3518150C1 (en) | 1985-05-21 | 1986-10-23 | Karl Prof. Dr.med. 7302 Ostfildern Theurer | Process for the production of suspendible corpuscular particles of adhesive materials with molecular long-fibre crosslinking |
US4627853A (en) | 1985-05-29 | 1986-12-09 | American Hospital Supply Corporation | Method of producing prostheses for replacement of articular cartilage and prostheses so produced |
US4637931A (en) | 1984-10-09 | 1987-01-20 | The United States Of America As Represented By The Secretary Of The Army | Polyactic-polyglycolic acid copolymer combined with decalcified freeze-dried bone for use as a bone repair material |
US4642120A (en) | 1983-03-23 | 1987-02-10 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Repair of cartilage and bones |
US4645669A (en) | 1982-10-04 | 1987-02-24 | Albert Einstein College Of Medicine Of Yeshiva University | Culturing and emplacement of differentiated cells in vivo |
US4675284A (en) | 1984-08-22 | 1987-06-23 | Leevy Carroll M | Process and apparatus for evaluating liver disease |
US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
US4681763A (en) | 1985-06-11 | 1987-07-21 | University Of Medicine And Dentistry Of New Jersey | Composition for stimulating bone growth |
US4689293A (en) | 1983-06-06 | 1987-08-25 | Connaught Laboratories Limited | Microencapsulation of living tissue and cells |
WO1987006120A1 (en) | 1986-04-18 | 1987-10-22 | Marrow-Tech Incorporated | Process for replicating bone marrow |
US4713070A (en) | 1978-11-30 | 1987-12-15 | Sumitom Electric Industries, Ltd. | Porous structure of polytetrafluoroethylene and process for production thereof |
US4721096A (en) | 1986-04-18 | 1988-01-26 | Marrow-Tech Incorporated | Process for replicating bone marrow in vitro and using the same |
US4734373A (en) | 1986-06-24 | 1988-03-29 | Bartal Arie H | Apparatus for enhancing cell growth, preservation and transport |
WO1988003785A1 (en) | 1986-11-20 | 1988-06-02 | Vacanti Joseph P | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
US4757017A (en) | 1984-09-14 | 1988-07-12 | Mcw Research Foundation, Inc. | In vitro cell culture system |
US4757128A (en) | 1986-08-01 | 1988-07-12 | Massachusetts Institute Of Technology | High molecular weight polyanhydride and preparation thereof |
EP0282746A1 (en) | 1987-02-19 | 1988-09-21 | Takeda Chemical Industries, Ltd. | Method for producing artificial cultured tissue |
US4778749A (en) | 1984-06-01 | 1988-10-18 | Karyon Technology, Inc. | Tissue culture and production in permeable gels |
US4795459A (en) * | 1987-05-18 | 1989-01-03 | Rhode Island Hospital | Implantable prosthetic device with lectin linked endothelial cells |
WO1989000413A1 (en) | 1987-07-20 | 1989-01-26 | Stone Kevin R | Prosthetic meniscus |
US4801299A (en) | 1983-06-10 | 1989-01-31 | University Patents, Inc. | Body implants of extracellular matrix and means and methods of making and using such implants |
US4846835A (en) | 1987-06-15 | 1989-07-11 | Grande Daniel A | Technique for healing lesions in cartilage |
US4853324A (en) | 1985-12-02 | 1989-08-01 | Viles Joseph M | Liver assist device employing transformed cell lines |
WO1989007944A1 (en) | 1988-02-24 | 1989-09-08 | American National Red Cross | Device for site directed neovascularization and method for same |
US4868121A (en) | 1985-02-07 | 1989-09-19 | Mcdonnell Douglas Corporation | Islet isolation process |
US4880622A (en) | 1986-05-20 | 1989-11-14 | Research Corporation Technologies, Inc. | Water-soluble phosphazene polymers having pharmacological applications |
US4886870A (en) | 1984-05-21 | 1989-12-12 | Massachusetts Institute Of Technology | Bioerodible articles useful as implants and prostheses having predictable degradation rates |
US4888176A (en) | 1984-05-21 | 1989-12-19 | Massachusetts Institute Of Technology | Controlled drug delivery high molecular weight polyanhydrides |
US4891225A (en) | 1984-05-21 | 1990-01-02 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
US4902289A (en) | 1982-04-19 | 1990-02-20 | Massachusetts Institute Of Technology | Multilayer bioreplaceable blood vessel prosthesis |
EP0344924A3 (en) | 1988-06-02 | 1990-03-07 | Organogenesis Inc. | Fibrin-collagen tissue equivalents and methods of preparation thereof |
EP0361957A1 (en) | 1988-09-30 | 1990-04-04 | Organogenesis Inc. | Tissue equivalents and methods of preparation thereof |
US4916193A (en) | 1987-12-17 | 1990-04-10 | Allied-Signal Inc. | Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides |
US4946938A (en) | 1989-08-01 | 1990-08-07 | The University Of Pittsburgh | A process for the catalytic synthesis of polyphosphazenes |
EP0248246B1 (en) | 1986-06-02 | 1990-09-19 | GebràDer Sulzer Aktiengesellschaft | Vascular graft wall |
US4963489A (en) | 1987-04-14 | 1990-10-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
WO1990012603A1 (en) | 1989-04-17 | 1990-11-01 | Vacanti Joseph P | Neomorphogenesis of cartilage in vivo from cell culture |
WO1990012604A1 (en) | 1989-04-25 | 1990-11-01 | Vacanti Joseph P | Method for implanting large volumes of cells on polymeric matrices |
US4988761A (en) | 1988-09-22 | 1991-01-29 | Dow Corning K.K. | Process for producing a low water content PVA hydrogel |
WO1991001720A1 (en) | 1989-08-07 | 1991-02-21 | Herman Wade Schlameus | Composition and method of promoting hard tissue healing |
US5032508A (en) | 1988-09-08 | 1991-07-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
US5078744A (en) * | 1987-09-04 | 1992-01-07 | Bio-Products, Inc. | Method of using tendon/ligament substitutes composed of long, parallel, non-antigenic tendon/ligament fibers |
EP0248247B1 (en) | 1986-06-02 | 1992-01-22 | GebràDer Sulzer Aktiengesellschaft | Vascular graft wall |
WO1992006702A1 (en) | 1990-10-19 | 1992-04-30 | New York University | A method for transplanting cells into the brain and therapeutic uses therefor |
WO1992007525A1 (en) | 1990-10-31 | 1992-05-14 | Baxter International Inc. | Close vascularization implant material |
EP0153896B1 (en) | 1984-02-21 | 1992-05-27 | BIOETICA, Société Anonyme | Biocompatible implantable containers based on collagen for the conservation and/or the cultivation of cells and/or the controlled liberation of active compounds |
EP0339607B1 (en) | 1988-04-29 | 1993-02-10 | Samuel Dr. Itay | Composition for repair of cartilage and bone and method for their preparation as skeletal tissue implant |
WO1993007913A1 (en) | 1991-10-24 | 1993-04-29 | Children's Medical Center Corporation | Neomorphogenesis of urological structures in vivo from cell culture |
US5207705A (en) * | 1988-12-08 | 1993-05-04 | Brigham And Women's Hospital | Prosthesis of foam polyurethane and collagen and uses thereof |
WO1993008850A1 (en) | 1991-10-30 | 1993-05-13 | Massachusetts Institute Of Technology | Prevascularized polymeric implants for organ transplantation |
US5219361A (en) | 1988-09-16 | 1993-06-15 | Clemson University | Soft tissue implant with micron-scale surface texture to optimize anchorage |
WO1993016687A1 (en) | 1992-02-28 | 1993-09-02 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
EP0226061B1 (en) | 1985-12-17 | 1994-02-16 | United States Surgical Corporation | High molecular weight bioresorbable polymers and implantation devices thereof |
US5324519A (en) | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
WO1994021299A1 (en) | 1993-03-19 | 1994-09-29 | Medinvent | A composition and a method for tissue augmentation |
WO1994025079A1 (en) | 1993-04-23 | 1994-11-10 | Massachusetts Institute Of Technology | Porous biodegradable polymeric materials for cell transplantation |
US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
US5514378A (en) * | 1993-02-01 | 1996-05-07 | Massachusetts Institute Of Technology | Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures |
US5709854A (en) | 1993-04-30 | 1998-01-20 | Massachusetts Institute Of Technology | Tissue formation by injecting a cell-polymeric solution that gels in vivo |
US5720981A (en) * | 1985-08-14 | 1998-02-24 | Sloan-Kettering Institute For Cancer Research | Epidermal cell extracts and method to enhance wound healing and regenerate epidermis |
US5772695A (en) | 1991-03-05 | 1998-06-30 | Colorado State University Research Foundation | Treated tissue for implantation and methods of treatment and use |
US5855608A (en) | 1994-05-13 | 1999-01-05 | Thm Biomedical, Inc. | Device and methods for in vivo culturing of diverse tissue cells |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE511546A (en) * | 1951-10-23 | |||
US3531551A (en) * | 1967-06-09 | 1970-09-29 | American Cyanamid Co | Dielectric curing of spandex |
GB1279915A (en) * | 1969-03-18 | 1972-06-28 | Knoll Ag | 0-aryl-2,3,4,5-tetrahydro-1h-1,5-benzodiazepine-2-ones and a process for their preparation |
DE2406693C3 (en) * | 1974-02-13 | 1981-01-22 | Benteler-Werke Ag Werk Neuhaus, 4790 Paderborn | Device for the transmission of direct current of high amperage and low harmonics to the rotating electrode disk during roller seam resistance butt welding |
GB1522603A (en) * | 1974-08-07 | 1978-08-23 | Nat Res Dev | Prosthetic devices |
FR2435050A1 (en) * | 1978-08-29 | 1980-03-28 | Commissariat Energie Atomique | DEVICE FOR ANALYZING THE ACTIVITY OF A RADIOACTIVE AEROSOL AS A FUNCTION OF THE GRANULOMETRY OF ITS PARTICLES |
US4494386A (en) * | 1982-03-15 | 1985-01-22 | Rovac Corporation | Vapor refrigeration cycle system with constrained rotary vane compressor and low vapor pressure refrigerant |
SE430669B (en) * | 1982-04-30 | 1983-12-05 | Lindskog K J E | SET FOR MANUFACTURING FIBER REFINED PLASTIC BODIES AND APPARATUS FOR USE IN SUCH MANUFACTURING |
DE3318150C2 (en) | 1983-05-18 | 1985-07-11 | Vsesojuznyj zaočnyj politechničeskij institut, Moskva | Working container for blow molding and sand shooting machines |
FR2560490B1 (en) | 1984-03-02 | 1986-12-19 | Boton Freres | CUTTING HEAD WITH MEANS OF REGULATING THE CUTTING PLANE FOR MATERIAL |
US4732636A (en) | 1986-05-23 | 1988-03-22 | International Business Machines Corporation | Method for producing a prepreg having improved dimensional stability |
-
1995
- 1995-05-19 US US08/445,280 patent/US5855610A/en not_active Expired - Lifetime
-
1998
- 1998-11-03 US US09/185,360 patent/US6348069B1/en not_active Ceased
-
2004
- 2004-02-19 US US10/782,750 patent/USRE42479E1/en not_active Expired - Lifetime
-
2006
- 2006-09-28 US US11/529,691 patent/USRE42575E1/en not_active Expired - Lifetime
Patent Citations (142)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1995970A (en) | 1931-04-04 | 1935-03-26 | Du Pont | Polymeric lactide resin |
US2609347A (en) | 1948-05-27 | 1952-09-02 | Wilson Christopher Lumley | Method of making expanded polyvinyl alcohol-formaldehyde reaction product and product resulting therefrom |
US2664366A (en) | 1949-09-19 | 1953-12-29 | Wilson Christopher Lumley | Plasticized sponge material and method of making same |
US2659935A (en) | 1950-03-18 | 1953-11-24 | Christopher L Wilson | Method of making compressed sponges |
US2653917A (en) | 1950-06-15 | 1953-09-29 | Christopher L Wilson | Method of making an expanded material and the product resulting therefrom |
US2676945A (en) | 1950-10-18 | 1954-04-27 | Du Pont | Condensation polymers of hydroxyacetic acid |
US2683136A (en) | 1950-10-25 | 1954-07-06 | Du Pont | Copolymers of hydroxyacetic acid with other alcohol acids |
US2703316A (en) | 1951-06-05 | 1955-03-01 | Du Pont | Polymers of high melting lactide |
US2758987A (en) | 1952-06-05 | 1956-08-14 | Du Pont | Optically active homopolymers containing but one antipodal species of an alpha-monohydroxy monocarboxylic acid |
US2846407A (en) | 1954-01-13 | 1958-08-05 | Wilson Christopher Lumley | Method of making a detergent and solvent resistant sponge material |
US2951828A (en) | 1957-03-04 | 1960-09-06 | Boehringer Sohn Ingelheim | Process for the production of bead polymerizates from cyclic internal esters of alpha-hydroxy carboxylic acids |
US3531561A (en) | 1965-04-20 | 1970-09-29 | Ethicon Inc | Suture preparation |
US3514791A (en) * | 1967-07-25 | 1970-06-02 | Charles H Sparks | Tissue grafts |
US3880991A (en) | 1969-03-24 | 1975-04-29 | Brook David E | Polymeric article for dispensing drugs |
US4069307A (en) | 1970-10-01 | 1978-01-17 | Alza Corporation | Drug-delivery device comprising certain polymeric materials for controlled release of drug |
US3935065A (en) | 1971-09-02 | 1976-01-27 | Roland Karl Doerig | Procedure for conservation of living organs and apparatus for the execution of this procedure |
US3960150A (en) | 1971-09-09 | 1976-06-01 | Alza Corporation | Bioerodible ocular device |
US4026304A (en) | 1972-04-12 | 1977-05-31 | Hydro Med Sciences Inc. | Bone generating method and device |
US3883393A (en) | 1972-05-18 | 1975-05-13 | Us Health Education & Welfare | Cell culture on semi-permeable tubular membranes |
US3826241A (en) | 1972-10-16 | 1974-07-30 | Investors In Ventures Inc | Implanting method |
US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
US3974526A (en) | 1973-07-06 | 1976-08-17 | Dardik Irving I | Vascular prostheses and process for producing the same |
US3992725A (en) | 1973-11-16 | 1976-11-23 | Homsy Charles A | Implantable material and appliances and method of stabilizing body implants |
US3902497A (en) | 1974-03-25 | 1975-09-02 | American Cyanamid Co | Body absorbable sponge and method of making |
US4192827A (en) | 1974-06-27 | 1980-03-11 | Ciba-Geigy Corporation | Water-insoluble hydrophilic copolymers |
US3995444A (en) | 1974-11-08 | 1976-12-07 | American Hospital Supply Corporation | Organ perfusion system |
US3949073A (en) | 1974-11-18 | 1976-04-06 | The Board Of Trustees Of Leland Stanford Junior University | Process for augmenting connective mammalian tissue with in situ polymerizable native collagen solution |
US4144126A (en) | 1975-05-21 | 1979-03-13 | Beecham Group Limited | Cell culture method |
US4060081A (en) | 1975-07-15 | 1977-11-29 | Massachusetts Institute Of Technology | Multilayer membrane useful as synthetic skin |
US4280954A (en) | 1975-07-15 | 1981-07-28 | Massachusetts Institute Of Technology | Crosslinked collagen-mucopolysaccharide composite materials |
US4186448A (en) | 1976-04-16 | 1980-02-05 | Brekke John H | Device and method for treating and healing a newly created bone void |
US4391797A (en) | 1977-01-05 | 1983-07-05 | The Children's Hospital Medical Center | Systems for the controlled release of macromolecules |
US4141087A (en) | 1977-01-19 | 1979-02-27 | Ethicon, Inc. | Isomorphic copolyoxalates and sutures thereof |
US4328204A (en) | 1977-03-02 | 1982-05-04 | Ethicon, Inc. | Absorbable polymer-drug compounds and method for making same |
US4205399A (en) | 1977-06-13 | 1980-06-03 | Ethicon, Inc. | Synthetic absorbable surgical devices of poly(alkylene oxalates) |
US4137921A (en) | 1977-06-24 | 1979-02-06 | Ethicon, Inc. | Addition copolymers of lactide and glycolide and method of preparation |
DE2853614A1 (en) | 1978-01-25 | 1979-07-26 | Bentley Lab | IMPLANT |
US4304591A (en) | 1978-01-25 | 1981-12-08 | Ciba-Geigy Corporation | Water-insoluble hydrophilic copolymers used as carriers for medicaments and pesticides |
US4277582A (en) | 1978-03-03 | 1981-07-07 | Ciba-Geigy Corporation | Water-insoluble hydrophilic copolymers |
US4228243A (en) | 1978-07-13 | 1980-10-14 | Toray Industries, Inc. | Cell culture propagation apparatus |
US4239664A (en) | 1978-10-31 | 1980-12-16 | Research Corporation | Anti-thrombogenic PVP-heparin polymer |
US4243775A (en) | 1978-11-13 | 1981-01-06 | American Cyanamid Company | Synthetic polyester surgical articles |
US4456687A (en) | 1978-11-16 | 1984-06-26 | President And Fellows Of Harvard College | Agents for promoting growth of epithelial cells |
US4713070A (en) | 1978-11-30 | 1987-12-15 | Sumitom Electric Industries, Ltd. | Porous structure of polytetrafluoroethylene and process for production thereof |
US4352883A (en) | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
US4304866A (en) | 1979-11-14 | 1981-12-08 | Massachusetts Institute Of Technology | Transplantable sheets of living keratinous tissue |
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4348329A (en) | 1979-12-20 | 1982-09-07 | Dennis Chapman | Biocompatible surfaces |
US4356261A (en) | 1980-04-22 | 1982-10-26 | Rush-Presbyterian-St. Luke's Medical Center | Anti-invasion factor containing cultures |
US4347847A (en) | 1980-06-06 | 1982-09-07 | Usher Francis C | Method of hernia repair |
US4563490A (en) | 1980-07-21 | 1986-01-07 | Czechoslovenska Akademie Ved Of Praha | Composite polymeric material for biological and medical application and the method for its preparation |
US4427808A (en) | 1980-07-21 | 1984-01-24 | Ceskoslovenska Akademie Ved | Composite polymeric material for biological and medical applications and the method for its preparation |
US4576608A (en) | 1980-11-06 | 1986-03-18 | Homsy Charles A | Porous body-implantable polytetrafluoroethylene |
US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
US4416986A (en) | 1981-01-16 | 1983-11-22 | Merck & Co., Inc. | Methods of producing HBsAg |
US4553272A (en) | 1981-02-26 | 1985-11-19 | University Of Pittsburgh | Regeneration of living tissues by growth of isolated cells in porous implant and product thereof |
US4438198A (en) | 1981-09-30 | 1984-03-20 | Trimedyne, Inc. | Biochemically active matrix for use in a bio-artificial organ |
US4431428A (en) | 1981-09-30 | 1984-02-14 | Trimedyne, Inc. | Bio-artificial organ using microencapsulated enzymes |
US4446234A (en) | 1981-10-23 | 1984-05-01 | The United States Of America As Represented By The Department Of Health And Human Services | Vitro cellular interaction with amnion membrane substrate |
US4458678A (en) | 1981-10-26 | 1984-07-10 | Massachusetts Institute Of Technology | Cell-seeding procedures involving fibrous lattices |
US4505266A (en) | 1981-10-26 | 1985-03-19 | Massachusetts Institute Of Technology | Method of using a fibrous lattice |
US4485096A (en) | 1982-02-26 | 1984-11-27 | Massachusetts Institute Of Technology | Tissue-equivalent and method for preparation thereof |
US4439152A (en) | 1982-03-04 | 1984-03-27 | Small Irwin A | Method of jawbone abutment implant for dental prostheses and implant device |
US4545082A (en) | 1982-03-25 | 1985-10-08 | Vascutek Limited | Vascular prosthesis |
US4902289A (en) | 1982-04-19 | 1990-02-20 | Massachusetts Institute Of Technology | Multilayer bioreplaceable blood vessel prosthesis |
US4520821A (en) | 1982-04-30 | 1985-06-04 | The Regents Of The University Of California | Growing of long-term biological tissue correction structures in vivo |
US4528265A (en) | 1982-05-11 | 1985-07-09 | Becker Robert O | Processes and products involving cell modification |
US4485097A (en) | 1982-05-26 | 1984-11-27 | Massachusetts Institute Of Technology | Bone-equivalent and method for preparation thereof |
US4494385A (en) | 1982-06-04 | 1985-01-22 | Hoxan Corporation | Method of preserving organ and apparatus for preserving the same |
US4440921A (en) | 1982-06-21 | 1984-04-03 | Research Corporation | Coupling of polyorganophosphazenes to carboxylic acid |
US4495174A (en) | 1982-06-21 | 1985-01-22 | Research Corporation | Anesthetic polyorganophosphazenes |
US4489056A (en) | 1982-06-30 | 1984-12-18 | Merck & Co., Inc. | Acid anhydrides as rate controlling agent for the erosion of polymers which latter polymers have beneficial substances dispersed throughout their matrix or where the polymer matrix surrounds the beneficial substance |
US4544516A (en) | 1982-07-28 | 1985-10-01 | Battelle Development Corporation | Collagen orientation |
US4559304A (en) | 1982-08-09 | 1985-12-17 | Koken Co., Ltd. | Substratum for cell culture and a method for culturing and isolating cells using same |
US4645669A (en) | 1982-10-04 | 1987-02-24 | Albert Einstein College Of Medicine Of Yeshiva University | Culturing and emplacement of differentiated cells in vivo |
US4559298A (en) | 1982-11-23 | 1985-12-17 | American National Red Cross | Cryopreservation of biological materials in a non-frozen or vitreous state |
US4446229A (en) | 1982-12-30 | 1984-05-01 | Indech Robert B | Method of tissue growth |
US4642120A (en) | 1983-03-23 | 1987-02-10 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Repair of cartilage and bones |
US4689293A (en) | 1983-06-06 | 1987-08-25 | Connaught Laboratories Limited | Microencapsulation of living tissue and cells |
US4801299A (en) | 1983-06-10 | 1989-01-31 | University Patents, Inc. | Body implants of extracellular matrix and means and methods of making and using such implants |
US4563489A (en) | 1984-02-10 | 1986-01-07 | University Of California | Biodegradable organic polymer delivery system for bone morphogenetic protein |
EP0153896B1 (en) | 1984-02-21 | 1992-05-27 | BIOETICA, Société Anonyme | Biocompatible implantable containers based on collagen for the conservation and/or the cultivation of cells and/or the controlled liberation of active compounds |
US4609551A (en) | 1984-03-20 | 1986-09-02 | Arnold Caplan | Process of and material for stimulating growth of cartilage and bony tissue at anatomical sites |
US4886870A (en) | 1984-05-21 | 1989-12-12 | Massachusetts Institute Of Technology | Bioerodible articles useful as implants and prostheses having predictable degradation rates |
US4888176A (en) | 1984-05-21 | 1989-12-19 | Massachusetts Institute Of Technology | Controlled drug delivery high molecular weight polyanhydrides |
US4891225A (en) | 1984-05-21 | 1990-01-02 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
US4778749A (en) | 1984-06-01 | 1988-10-18 | Karyon Technology, Inc. | Tissue culture and production in permeable gels |
US4675284A (en) | 1984-08-22 | 1987-06-23 | Leevy Carroll M | Process and apparatus for evaluating liver disease |
US4757017A (en) | 1984-09-14 | 1988-07-12 | Mcw Research Foundation, Inc. | In vitro cell culture system |
US4637931A (en) | 1984-10-09 | 1987-01-20 | The United States Of America As Represented By The Secretary Of The Army | Polyactic-polyglycolic acid copolymer combined with decalcified freeze-dried bone for use as a bone repair material |
US4563350A (en) | 1984-10-24 | 1986-01-07 | Collagen Corporation | Inductive collagen based bone repair preparations |
US4595713A (en) | 1985-01-22 | 1986-06-17 | Hexcel Corporation | Medical putty for tissue augmentation |
US4868121A (en) | 1985-02-07 | 1989-09-19 | Mcdonnell Douglas Corporation | Islet isolation process |
DE3518150C1 (en) | 1985-05-21 | 1986-10-23 | Karl Prof. Dr.med. 7302 Ostfildern Theurer | Process for the production of suspendible corpuscular particles of adhesive materials with molecular long-fibre crosslinking |
US4627853A (en) | 1985-05-29 | 1986-12-09 | American Hospital Supply Corporation | Method of producing prostheses for replacement of articular cartilage and prostheses so produced |
US4681763A (en) | 1985-06-11 | 1987-07-21 | University Of Medicine And Dentistry Of New Jersey | Composition for stimulating bone growth |
US5720981A (en) * | 1985-08-14 | 1998-02-24 | Sloan-Kettering Institute For Cancer Research | Epidermal cell extracts and method to enhance wound healing and regenerate epidermis |
US4853324A (en) | 1985-12-02 | 1989-08-01 | Viles Joseph M | Liver assist device employing transformed cell lines |
EP0226061B1 (en) | 1985-12-17 | 1994-02-16 | United States Surgical Corporation | High molecular weight bioresorbable polymers and implantation devices thereof |
WO1987006120A1 (en) | 1986-04-18 | 1987-10-22 | Marrow-Tech Incorporated | Process for replicating bone marrow |
US4721096A (en) | 1986-04-18 | 1988-01-26 | Marrow-Tech Incorporated | Process for replicating bone marrow in vitro and using the same |
US4880622A (en) | 1986-05-20 | 1989-11-14 | Research Corporation Technologies, Inc. | Water-soluble phosphazene polymers having pharmacological applications |
EP0248247B1 (en) | 1986-06-02 | 1992-01-22 | GebràDer Sulzer Aktiengesellschaft | Vascular graft wall |
EP0248246B1 (en) | 1986-06-02 | 1990-09-19 | GebràDer Sulzer Aktiengesellschaft | Vascular graft wall |
US4734373A (en) | 1986-06-24 | 1988-03-29 | Bartal Arie H | Apparatus for enhancing cell growth, preservation and transport |
US4757128A (en) | 1986-08-01 | 1988-07-12 | Massachusetts Institute Of Technology | High molecular weight polyanhydride and preparation thereof |
US5770193A (en) | 1986-11-20 | 1998-06-23 | Massachusetts Institute Of Technology Children's Medical Center Corporation | Preparation of three-dimensional fibrous scaffold for attaching cells to produce vascularized tissue in vivo |
WO1988003785A1 (en) | 1986-11-20 | 1988-06-02 | Vacanti Joseph P | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
US5041138A (en) | 1986-11-20 | 1991-08-20 | Massachusetts Institute Of Technology | Neomorphogenesis of cartilage in vivo from cell culture |
EP0282746A1 (en) | 1987-02-19 | 1988-09-21 | Takeda Chemical Industries, Ltd. | Method for producing artificial cultured tissue |
US4963489A (en) | 1987-04-14 | 1990-10-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
US4795459A (en) * | 1987-05-18 | 1989-01-03 | Rhode Island Hospital | Implantable prosthetic device with lectin linked endothelial cells |
US4846835A (en) | 1987-06-15 | 1989-07-11 | Grande Daniel A | Technique for healing lesions in cartilage |
WO1989000413A1 (en) | 1987-07-20 | 1989-01-26 | Stone Kevin R | Prosthetic meniscus |
AU2424588A (en) | 1987-07-20 | 1989-02-13 | Kevin R. Stone | Prosthetic meniscus |
US5078744A (en) * | 1987-09-04 | 1992-01-07 | Bio-Products, Inc. | Method of using tendon/ligament substitutes composed of long, parallel, non-antigenic tendon/ligament fibers |
US4916193A (en) | 1987-12-17 | 1990-04-10 | Allied-Signal Inc. | Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides |
WO1989007944A1 (en) | 1988-02-24 | 1989-09-08 | American National Red Cross | Device for site directed neovascularization and method for same |
EP0339607B1 (en) | 1988-04-29 | 1993-02-10 | Samuel Dr. Itay | Composition for repair of cartilage and bone and method for their preparation as skeletal tissue implant |
EP0344924A3 (en) | 1988-06-02 | 1990-03-07 | Organogenesis Inc. | Fibrin-collagen tissue equivalents and methods of preparation thereof |
US5032508A (en) | 1988-09-08 | 1991-07-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
US5219361A (en) | 1988-09-16 | 1993-06-15 | Clemson University | Soft tissue implant with micron-scale surface texture to optimize anchorage |
US4988761A (en) | 1988-09-22 | 1991-01-29 | Dow Corning K.K. | Process for producing a low water content PVA hydrogel |
EP0361957A1 (en) | 1988-09-30 | 1990-04-04 | Organogenesis Inc. | Tissue equivalents and methods of preparation thereof |
US5207705A (en) * | 1988-12-08 | 1993-05-04 | Brigham And Women's Hospital | Prosthesis of foam polyurethane and collagen and uses thereof |
WO1990012603A1 (en) | 1989-04-17 | 1990-11-01 | Vacanti Joseph P | Neomorphogenesis of cartilage in vivo from cell culture |
WO1990012604A1 (en) | 1989-04-25 | 1990-11-01 | Vacanti Joseph P | Method for implanting large volumes of cells on polymeric matrices |
US5324519A (en) | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
US4946938A (en) | 1989-08-01 | 1990-08-07 | The University Of Pittsburgh | A process for the catalytic synthesis of polyphosphazenes |
WO1991001720A1 (en) | 1989-08-07 | 1991-02-21 | Herman Wade Schlameus | Composition and method of promoting hard tissue healing |
WO1992006702A1 (en) | 1990-10-19 | 1992-04-30 | New York University | A method for transplanting cells into the brain and therapeutic uses therefor |
WO1992007525A1 (en) | 1990-10-31 | 1992-05-14 | Baxter International Inc. | Close vascularization implant material |
US5772695A (en) | 1991-03-05 | 1998-06-30 | Colorado State University Research Foundation | Treated tissue for implantation and methods of treatment and use |
WO1993007913A1 (en) | 1991-10-24 | 1993-04-29 | Children's Medical Center Corporation | Neomorphogenesis of urological structures in vivo from cell culture |
WO1993008850A1 (en) | 1991-10-30 | 1993-05-13 | Massachusetts Institute Of Technology | Prevascularized polymeric implants for organ transplantation |
WO1993016687A1 (en) | 1992-02-28 | 1993-09-02 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
US5514378A (en) * | 1993-02-01 | 1996-05-07 | Massachusetts Institute Of Technology | Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures |
WO1994021299A1 (en) | 1993-03-19 | 1994-09-29 | Medinvent | A composition and a method for tissue augmentation |
WO1994025079A1 (en) | 1993-04-23 | 1994-11-10 | Massachusetts Institute Of Technology | Porous biodegradable polymeric materials for cell transplantation |
US5709854A (en) | 1993-04-30 | 1998-01-20 | Massachusetts Institute Of Technology | Tissue formation by injecting a cell-polymeric solution that gels in vivo |
US5855608A (en) | 1994-05-13 | 1999-01-05 | Thm Biomedical, Inc. | Device and methods for in vivo culturing of diverse tissue cells |
Non-Patent Citations (211)
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100222882A1 (en) * | 2009-02-27 | 2010-09-02 | Badylak Stephen F | Joint bioscaffolds |
US9277999B2 (en) | 2009-02-27 | 2016-03-08 | University of Pittsburgh—of the Commonwealth System of Higher Education | Joint bioscaffolds |
US9314340B2 (en) | 2009-02-27 | 2016-04-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Joint bioscaffolds |
US9848987B2 (en) | 2009-02-27 | 2017-12-26 | University of Pittsburgh — Of the Commonwealth System of Higher Education | Joint bioscaffolds |
US9801910B2 (en) | 2014-03-17 | 2017-10-31 | Ethicon, Inc. | Decellularized pleural matrix |
Also Published As
Publication number | Publication date |
---|---|
US6348069B1 (en) | 2002-02-19 |
US5855610A (en) | 1999-01-05 |
USRE42479E1 (en) | 2011-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE42575E1 (en) | Engineering of strong, pliable tissues | |
EP0739631B1 (en) | Laminar bone support for cartilage growth | |
Shum-Tim et al. | Tissue engineering of autologous aorta using a new biodegradable polymer | |
US5041138A (en) | Neomorphogenesis of cartilage in vivo from cell culture | |
US7914579B2 (en) | Tissue engineered tendons and ligaments | |
US5567612A (en) | Genitourinary cell-matrix structure for implantation into a human and a method of making | |
US5736372A (en) | Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure | |
US5851833A (en) | Neomorphogenesis of urological structures in vivo from cell culture | |
EP0299010B1 (en) | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices | |
US8663675B2 (en) | Injectable matrix having a polymer and a stem cell niche composed of cup-shaped nanoparticles containing growth factors or physiological agents for organ reconstruction | |
US8748142B2 (en) | Culture of cardiovascular cells on a matrix and method for regenerating cardiovascular tissue | |
JP4854670B2 (en) | Structural skeletal engineering | |
JPH10505250A (en) | Biomatrix for tissue regeneration | |
CA2330104A1 (en) | Creation of three-dimensional tissues | |
WO2001003750A1 (en) | Human naturally secreted extracellular matrix-coated device | |
Stock et al. | Valves in development for autogenous tissue valve replacement | |
Goulet et al. | Tissue-engineered ligament | |
Atala | SSI Grand Master Lecture 2'Tissue engineering applications for erectile dysfunction'. | |
Ikada | Why is the Clinical Application of Tissue Engineering So Slow? | |
Shin'oka et al. | Current status of tissue engineering for cardiovascular structures | |
Kim | The role of mechanical stimuli in engineered smooth muscle tissue development | |
Daniel Eberli et al. | COMPOSITE SCAFFOLDS FOR THE ENGINEERING OF HOLLOW ORGANS AND |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FPAY | Fee payment |
Year of fee payment: 12 |